WO2004069823A1 - Inhibitors of histone deacetylase - Google Patents
Inhibitors of histone deacetylase Download PDFInfo
- Publication number
- WO2004069823A1 WO2004069823A1 PCT/CA2004/000139 CA2004000139W WO2004069823A1 WO 2004069823 A1 WO2004069823 A1 WO 2004069823A1 CA 2004000139 W CA2004000139 W CA 2004000139W WO 2004069823 A1 WO2004069823 A1 WO 2004069823A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mmol
- amino
- phenyl
- yield
- compound
- Prior art date
Links
- 0 CC(C)(C=CC(C)(C)c(cc1)ccc1I)C(N*)=O Chemical compound CC(C)(C=CC(C)(C)c(cc1)ccc1I)C(N*)=O 0.000 description 5
- YVANRIGGPVNAGU-UHFFFAOYSA-N CC(C1C2=CC=CC1)OC2=O Chemical compound CC(C1C2=CC=CC1)OC2=O YVANRIGGPVNAGU-UHFFFAOYSA-N 0.000 description 1
- UNYSHAZVCIFGCA-UHFFFAOYSA-N CC(N1Cc(cc2)ccc2C(Nc(cccc2)c2N)=O)=Nc2ccccc2C1=O Chemical compound CC(N1Cc(cc2)ccc2C(Nc(cccc2)c2N)=O)=Nc2ccccc2C1=O UNYSHAZVCIFGCA-UHFFFAOYSA-N 0.000 description 1
- OTEAQWLBFSVFHK-UHFFFAOYSA-N CCN1c2ccccc2OC(Cc(cc2)ccc2C(OC)=O)C1=O Chemical compound CCN1c2ccccc2OC(Cc(cc2)ccc2C(OC)=O)C1=O OTEAQWLBFSVFHK-UHFFFAOYSA-N 0.000 description 1
- YPQYPYHZSJNTAV-GDNBJRDFSA-N COC(c1ccc(/C=C(/Cc2ccccc22)\C2=O)cc1)=O Chemical compound COC(c1ccc(/C=C(/Cc2ccccc22)\C2=O)cc1)=O YPQYPYHZSJNTAV-GDNBJRDFSA-N 0.000 description 1
- FJWVIQKPWKBNHL-UHFFFAOYSA-N COC(c1ccc(CC2Oc(cccc3)c3NC2=O)cc1)=O Chemical compound COC(c1ccc(CC2Oc(cccc3)c3NC2=O)cc1)=O FJWVIQKPWKBNHL-UHFFFAOYSA-N 0.000 description 1
- IDPURXSQCKYKIJ-UHFFFAOYSA-N COc1ccc(CN)cc1 Chemical compound COc1ccc(CN)cc1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- YXBTVKUIIVLRQF-UHFFFAOYSA-N COc1cccc(-c(nc2)ccc2C(Nc2ccccc2N)=O)c1 Chemical compound COc1cccc(-c(nc2)ccc2C(Nc2ccccc2N)=O)c1 YXBTVKUIIVLRQF-UHFFFAOYSA-N 0.000 description 1
- BEXSXUCNKNTNHN-UHFFFAOYSA-N COc1nc(NCc(cc2)ccc2C(Nc2ccccc2N)=O)nc(NC(C2)=CC3=C2CCC=C3)n1 Chemical compound COc1nc(NCc(cc2)ccc2C(Nc2ccccc2N)=O)nc(NC(C2)=CC3=C2CCC=C3)n1 BEXSXUCNKNTNHN-UHFFFAOYSA-N 0.000 description 1
- HQLCSBNBUKZUCX-UHFFFAOYSA-N COc1nc(NCc(cc2)ccc2C(O)=O)nc(NC2Cc3ccccc3C2)n1 Chemical compound COc1nc(NCc(cc2)ccc2C(O)=O)nc(NC2Cc3ccccc3C2)n1 HQLCSBNBUKZUCX-UHFFFAOYSA-N 0.000 description 1
- NFNKGTWGESBLEY-UHFFFAOYSA-N Nc1ccccc1NC(c(cn1)ccc1Cl)=O Chemical compound Nc1ccccc1NC(c(cn1)ccc1Cl)=O NFNKGTWGESBLEY-UHFFFAOYSA-N 0.000 description 1
- QPOXAHHWWQYERQ-UHFFFAOYSA-N Nc1ccccc1NC(c1ccc(CN(C(c2ccccc22)=O)C2=O)cc1)=O Chemical compound Nc1ccccc1NC(c1ccc(CN(C(c2ccccc22)=O)C2=O)cc1)=O QPOXAHHWWQYERQ-UHFFFAOYSA-N 0.000 description 1
- QRCGFTXRXYMJOS-UHFFFAOYSA-N O=C1Nc2ccccc2OC1 Chemical compound O=C1Nc2ccccc2OC1 QRCGFTXRXYMJOS-UHFFFAOYSA-N 0.000 description 1
- RWIVICVCHVMHMU-UHFFFAOYSA-O [NH3+]CCN1CCOCC1 Chemical compound [NH3+]CCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/44—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/80—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/59—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
- C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
- C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C275/36—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with at least one of the oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. N-aryloxyphenylureas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/42—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/33—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring
- C07C323/35—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring the thio group being a sulfide group
- C07C323/36—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring the thio group being a sulfide group the sulfur atom of the sulfide group being further bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/43—Y being a hetero atom
- C07C323/44—X or Y being nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
- C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/54—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/70—Sulfur atoms
- C07D277/74—Sulfur atoms substituted by carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/28—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
- C07D311/56—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Definitions
- This invention relates to the inhibition of histone deacetylase. More particularly, the invention relates to compounds and methods for inhibiting histone deacetylase enzymatic activity.
- chromatin In eukaryotic cells, nuclear DNA associates with histones to form a compact complex called chromatin.
- the histones constitute a family of basic proteins which are generally highly conserved across eukaryotic species.
- the core histones termed H2A, H2B, H3, and H4, associate to form a protein core.
- DNA winds around this protein core, with the basic amino acids of the histones interacting with the negatively charged phosphate groups of the DNA.
- Approximately 146 base pairs of DNA wrap around a histone core to make up a nucleosome particle, the repeating structural motif of chromatin.
- histones are subject to posttranslational acetylation of the ⁇ e ⁇ -amino groups of JV-terminal lysine residues, a reaction that is catalyzed by histone acetyl transferase (HAT1) .
- HAT1 histone acetyl transferase
- Acetylation neutralizes the positive charge of the lysine side chain, and is thought to impact chromatin structure.
- Taunton et al . Science, 272: 408-411 (1996), teaches that access of transcription factors to chromatin templates is enhanced by histone hyperacetylation. Taunton et al .
- Histone acetylation is a reversible modification, with deacetylation being catalyzed by a family of enzymes termed histone deacetylases (HDACs) .
- HDACs histone deacetylases
- HDAC4 HDAC5
- HDAC6 HDAC6
- Kao et al . Genes & Dev. , 14: 55-66 (2000), discloses HDAC7, a new member of the second class of HDACs.
- TSA trichostatin A
- SAHA suberoylanilide hydroxamic acid
- HDACs may be divided into two classes, the first represented by yeast Rpd3-like proteins, and the second represented by yeast Hdal-like proteins. Grozinger et al . also teaches that the human HDAC-1, HDAC-2, and HDAC-3 proteins are members of the first class of HDACs, and discloses new proteins, named HDAC-4, HDAC-5, and HDAC-6, which are members of the second class of HDACs. Kao et al . , Gene & Development 14:55-66 (2000), discloses an additional member of this second class, called HDAC-7. More recently, Hu, E. et al . J.
- the invention provides compounds and methods for treating cell proliferative diseases.
- the invention provides new inhibitors of histone deacetylase enzymatic activity.
- the invention provides compounds that are useful as inhibitors of histone deacetylase.
- the invention provides a composition comprising an inhibitor of histone deacetylase according to the invention and a pharmaceutically acceptable carrier, excipient, or diluent .
- the invention provides a method of inhibiting histone deacetylase in a cell, comprising contacting a cell in which inhibition of histone deacetylase is desired with an inhibitor of histone deacetylase of the invention.
- Figure 1 is a graph showing the antitumor activity of compound 106 in an HCT 116 human colorectal tumor model.
- Figures 2-11 show additional data for other compounds used in the in vivo experiment described in Assay Example 2.
- the invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity.
- the invention also provides compositions and methods for treating cell proliferative diseases and conditions.
- the patent and scientific literature referred to herein establishes knowledge that is available to those with skill in the art.
- the issued patents, applications, and references that are cited herein are hereby incorporated by reference to the same extent as if each was specifically and individually indicated to be incorporated by reference. In the case of inconsistencies, the present disclosure will prevail.
- the following definitions will be used (unless expressly stated otherwise) :
- histone deacetylase and "HDAC” are intended to refer to any one of a family of enzymes that, remove acetyl groups from the ⁇ e ⁇ -amino groups of lysine residues at the N-terminus of a histone. Unless otherwise indicated by context, the term
- histone is meant to refer to any histone protein, including HI, H2A,
- histone deacetylases include class I and class II enzymes.
- the histone deacetylase is a human HDAC, including, but not limited to, HDAC-1,
- the histone deacetylase is derived from a protozoal or fungal source .
- histone deacetylase inhibitor and “inhibitor of histone deacetylase” are used to identify a compound having a structure as defined herein, which is capable of interacting with a histone deacetylase and inhibiting its enzymatic activity.
- “Inhibiting histone deacetylase enzymatic activity” means reducing the' ability of a histone deacetylase to remove an acetyl group from a histone. In some preferred embodiments, such reduction of histone deacetylase activity is at least about 50%, more preferably at least about 75%, and still more preferably at least about 90%. In other preferred embodiments, histone deacetylase activity is reduced by at least 95% and more preferably by at least 99%.
- the histone deacetylase inhibitor reduces the ability of a histone deacetylase to remove an acetyl group from a histone at a concentration that is lower than the concentration of the inhibitor that is required to produce another, unrelated biological effect.
- the concentration of the inhibitor required for histone deacetylase inhibitory activity is at least 2-fold lower, more preferably at least 5-fold lower, even more preferably at least 10-fold lower, and most preferably at least
- a bivalent linking moiety can be "alkyl,” in which case those skilled in the art will understand the alkyl to be a divalent radical (e.g., -CH 2 -CH 2 -) , which is equivalent to the term "alkylene.”
- alkyl a divalent radical
- aryl a divalent moiety that is required and is stated as being “aryl”
- All atoms are understood to have their normal number of valences for bond formation (i.e., 4 for carbon, 3 for N, 2 for O, and 2, 4, or 6 for S, depending on the oxidation state of the S) .
- a moiety may be defined, for • example, as (A) a -B-, wherein a is 0 or 1. In such instances, when a is 0 the moiety is B- and when a is 1 the moiety is A-B- . Also, a number of moieties disclosed herein exist in multiple tautomeric forms, all of which are intended to be encompassed by any given tautomeric structure.
- hydrocarbyl refers to a straight, branched, or cyclic alkyl, alkenyl, or alkynyl, each as defined herein.
- a “C 0 " hydrocarbyl is used to refer to a covalent bond.
- C 0 -C 3 - hydrocarbyl includes a covalent bond, methyl, ethyl, propyl, and eyelopropy1.
- alkyl refers to straight and branched chain aliphatic groups having from 1 to 12 carbon atoms, preferably 1-8 carbon atoms, and more preferably 1-6 carbon atoms, which is optionally substituted with one, two or three substituents .
- Preferred alkyl groups include, without limitation, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, and hexyl .
- a *C 0 " alkyl (as in "C 0 -C 3 -alkyl") is a covalent bond (like "C o " hydrocarbyl) .
- alkenyl as used herein means an unsaturated straight or branched chain aliphatic group with one or more carbon- carbon double bonds, having from 2 to 12 carbon atoms, preferably 2-8 carbon atoms, and more preferably 2-6 carbon atoms, which is optionally substituted with one, two or three substituents.
- Preferred alkenyl groups include, without limitation, ethenyl, propenyl, butenyl, pentenyl, and hexenyl .
- alkynyl as used herein means an unsaturated straight or branched chain aliphatic group with one or more carbon- carbon triple bonds, having from 2 to 12 carbon atoms, preferably 2-8 carbon atoms, and more preferably 2-6 carbon atoms, which is optionally substituted with one, two or three substituents.
- Preferred alkynyl groups include, without limitation, ethynyl, propynyl, butynyl , pentynyl , and hexynyl .
- alkylene is an alkyl, alkenyl, or alkynyl group, as defined hereinabove, that is positioned between and serves to connect two other chemical groups .
- Preferred alkylene groups include, without limitation, methylene, ethylene, propylene, and butylene.
- Preferred alkenylene groups include, without limitation, ethenylene, propenylene, and butenylene.
- Preferred alkynylene groups include, without limitation, ethynylene, propynylene, and butynylene.
- cycloalkyl as employed herein includes saturated and partially unsaturated cyclic hydrocarbon groups having 3 to 12 carbons, preferably 3 to 8 carbons, and more preferably 3 to 6 carbons, wherein the cycloalkyl group additionally is optionally substituted.
- Preferred cycloalkyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl .
- heteroalkyl refers to an alkyl group, as defined hereinabove, wherein one or more carbon atoms in the chain are replaced by a heteratom selected from the group consisting of 0, S, and N.
- An "aryl” group is a C 6 -C ⁇ 4 aromatic moiety comprising one to three aromatic rings, which is optionally substituted.
- the aryl group is a C 6 -C 10 aryl group.
- Preferred aryl groups include, without limitation, phenyl, naphthyl, anthracenyl, and fluorenyl .
- An "aralkyl” or “arylalkyl” group comprises an aryl group covalently linked to an alkyl group, either of which may independently be optionally substituted or unsubstituted.
- the aralkyl group is (C ⁇ -C 3 ) alk(C 6 -C ⁇ 0 ) aryl, including, without limitation, benzyl, phenethyl , and naphthylmethyl .
- a “heterocyclyl” or “heterocyclic” group is a ring structure having from about 3 to about 8 atoms, wherein one or more atoms are selected from the group consisting of N, 0, and S.
- the heterocyclic group is optionally substituted on carbon at one or more positions.
- the heterocyclic group is also independently optionally substituted on nitrogen with alkyl, aryl, aralkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, alkoxycarbonyl, aralkoxycarbonyl, or on sulfur with oxo or lower alkyl .
- Preferred heterocyclic groups include, without limitation, epoxy, aziridinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, thiazolidinyl, oxazolidinyl, oxazolidinonyl, and morpholino.
- the heterocyclic group is fused to an aryl, heteroaryl, or cycloalkyl group.
- fused heterocyles include, without limitation, tetrahydroquinoline and dihydrobenzofuran.
- tetrahydroquinoline and dihydrobenzofuran.
- compounds having adjacent annular O and/or S atoms are also included.
- heteroaryl refers to groups having
- heteroalkyl or “heteroarylalkyl” group comprises a heteroaryl group covalently linked to an alkyl group, either of which is independently optionally substituted or unsubstituted.
- Preferred heteroalkyl groups comprise a
- C;-C 6 alkyl group and a heteroaryl group having 5, 6, 9, or 10 ring atoms are compounds having adjacent annular 0 and/or S atoms.
- preferred heteroaralkyl groups include pyridylmethyl, pyridylethyl , pyrrolylmethyl , pyrrolylethyl, imidazolylmethyl , imidazolylethyl, thiazolylmethyl, and thiazolylethyl .
- compounds having adjacent annular 0 and/or S atoms are compounds having adjacent annular 0 and/or S atoms .
- arylene is an aryl, heteroaryl, or heterocyclyl group, as defined hereinabove, that is positioned between and serves to connect two other chemical groups .
- Preferred heterocyclyls and heteroaryls include, but are not limited to, acridinyl, azocinyl, benzimidazolyl, benzofuranyl , benzothiofuranyl , benzothiophenyl , benzoxazolyl , benzthiazolyl , benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H, 6H-1, 5,2-dithiazinyl, dihydrofuro [2 , 3 -b] tetrahydrofuran, furanyl, furazanyl, imidazolidinyl , imidazolinyl, imidazolyl, l
- a moiety e.g., cycloalkyl, hydrocarbyl, aryl, heteroaryl, heterocyclic, urea, etc.
- a moiety e.g., cycloalkyl, hydrocarbyl, aryl, heteroaryl, heterocyclic, urea, etc.
- the group optionally has from one to four, preferably from one to three, more preferably one or two, non-hydrogen substituents.
- Suitable substituents include, without limitation, halo, hydroxy, oxo (e.g., an annular -CH- substituted with oxo is -C(O)-) nitro, halohydrocarbyl , hydrocarbyl, aryl, aralkyl, alkoxy, aryloxy, amino, acylamino, alkylcarbamoyl, arylcarbamoyl, aminoalkyl, acyl, carboxy, hydroxyalkyl , , alkanesulfonyl, arenesulfonyl, alkanesulfonamido, arenesulfonamido, aralkylsulfonamido, alkylcarbonyl, acyloxy, cyano, and ureido groups. Preferred substituents, which are themselves not further substituted
- R 30 and R 31 are each independently hydrogen, cyano, oxo, carboxamido, amidino, C ⁇ -C 8 hydroxyalkyl, C 1 -C 3 alkylaryl, aryl-C ⁇ -C 3 alkyl, C x -C 8 alkyl, C ⁇ -C 8 alkenyl, C x -C 8 alkoxy, C ⁇ -C 8 alkoxycarbonyl, aryloxycarbonyl, aryl-C ⁇ -C 3 alkoxycarbonyl, C 2 -C 8 acyl, C x -C 8 alkylsulfonyl, arylalkylsulfonyl, arylsulfonyl, aroyl, aryl, cycloalkyl, heterocyclyl, or heteroary
- R 30 and R 31 taken together with the N to which they are attached form a heterocyclyl or heteroaryl, each of which is optionally substituted with from 1 to 3 substituents from (a), above.
- substituents on cyclic moieties include 5-6 membered mono- and 10-12 membered bi-cyclic moieties fused to the parent cyclic moiety to form a bi- or tri-cyclic fused ring system.
- an optionally substituted phenyl includes the following:
- halohydrocarbyl is a hydrocarbyl moiety in which from one to all hydrogens have been replaced with one or more halo.
- halogen or "halo" as employed herein refers to chlorine, bromine, fluorine, or iodine. As herein employed, the term
- acyl refers to an alkylcarbonyl or arylcarbonyl substituent.
- acylamino refers to an amide group attached at the nitrogen atom (i.e., R-CO-NH-) .
- carbamoyl refers to an amide group attached at the carbonyl carbon atom (i.e., NH 2 -CO-) .
- the nitrogen atom of an acylamino or carbamoyl substituent is additionally substituted.
- sulfonamido refers to a sulfonamide substituent attached by either the sulfur or the nitrogen atom.
- amino is meant to include NH 2 , alkylamino, arylamino, and cyclic amino groups.
- ureido refers to a substituted or unsubstituted urea moiety.
- radical means a chemical moiety comprising one or more unpaired electrons.
- a moiety that is substituted is one in which one or more hydrogens have been independently replaced with another chemical substituent.
- substituted phenyls include
- substituted n-octyls include 2,4 dimethyl-5-ethyl-octyl and 3-cyclopentyl-octyl . Included within this definition are methylenes (-CH 2 -) substituted with oxygen to form carbonyl -CO-) .
- an "unsubstituted" moiety as defined above e.g., unsubstituted cycloalkyl, unsubstituted heteroaryl, etc. means that moiety as defined above that does not have any of the optional substituents for which the definition of the moiety (above) otherwise provides.
- an "aryl” includes phenyl and phenyl substituted with a halo
- "unsubstituted aryl” does not include phenyl substituted with a halo.
- Preferred embodiments of a particular genus of compounds of the invention include combinations of preferred embodiments .
- paragraph [0043] identifies a preferred Ay 1 and paragraph
- Another preferred embodiment includes those compounds of formula (1) in paragraph [0042] in which Ay 1 is as defined in paragraph [0043] and Ar 1 is as defined in paragraph [0047] .
- the invention provides novel inhibitors of histone deacetylase.
- the novel inhibitors of histone deacetylase are represented by formula (1) :
- R 3 and R 4 are independently selected from the group consisting of hydrogen, L 1 , Cy 1 , and -L 1 -Cy 1 , wherein
- L 1 is C ⁇ -C 6 alkyl, C 2 -C 6 heteroalkyl, or C 3 -C 6 alkenyl; and Cy 1 is cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which optionally is substituted, and each of which optionally is fused to one or more aryl or heteroaryl rings, or to one or more saturated or partially unsaturated cycloalkyl or heterocyclic rings, each of which rings optionally is substituted; or
- R 3 and R 4 are taken together with the adjacent nitrogen atom to form a 5-, 6-, or 7-membered ring, wherein the ring atoms are independently selected from the group consisting of C, O, S, and N, and wherein the ring optionally is substituted, and optionally forms part of a bicyclic ring system, or optionally is fused to one or more aryl or heteroaryl rings, or to one or more saturated or partially unsaturated cycloalkyl or heterocyclic rings, each of which rings and ring systems optionally is substituted;
- Y 1 is selected from the group consisting of -N(R 1 ) (R 2 ) , -CH 2 -C(0)- N(R 1 ) (R 2 ) , halogen, and hydrogen, wherein
- R 1 and R 2 are independently selected from the group consisting of hydrogen, L 1 , Cy 1 , and -L 1 -Cy 1 , wherein
- L 1 is C ! -C 6 alkyl, C 2 -C 3 heteroalkyl, or C 3 -C 6 alkenyl; and Cy 1 is cycloalkyl, aryl, heteroaryl,' or heterocyclyl, each of which optionally is substituted, and each of which optionally is fused to one or more aryl or heteroaryl rings, or to one or more saturated or partially unsaturated cycloalkyl or heterocyclic rings, each of which rings optionally is substituted; or R 1 and R 2 are taken together with the " adjacent nitrogen atom to form a 5-, 6-, or 7-membered ring, wherein the ring atoms are independently selected from the group consisting of C, O, S, and N, and wherein the ring optionally is substituted, and optionally may form part of a bicyclic ring system, or optionally is fused to one or more aryl or heteroaryl rings, or to one or more saturated or partially unsaturated cycloalkyl or heterocyclic
- Ak 1 is C x -C 3 alkylene, C x -Cg-heteroalkylene (preferably, in which one -CH 2 - is replaced with -NH-, and more preferably -NH-CH 2 -) , C 2 -C 3 alkenylene or C 2 -C 3 alkynylene;
- Ar 1 is arylene or heteroarylene, either of which optionally is substituted;
- Z 1 is selected from the group consisting of
- Ay 1 is aryl or heteroaryl, which optionally is substituted.
- Ay 1 is phenyl or thienyl, each substituted with -OH or -NH 2 .
- Ay 1 is optionally amino- or hydroxy-substituted phenyl or thienyl, wherein the amino or hydroxy substituent is preferably ortho to the nitrogen to which Ay 2 is attached.
- Ay 1 is ortho aniline, ortho phenol, 3 -amino-2-thienyl, or 3- hydroxy-2-thienyl, and tautomers thereof.
- Ar 1 is phenylene.
- Ak 1 is alkylene, preferably methylene. in some preterre ⁇ embodiments, ⁇ is
- Y 1 is -N(R 1 ) (R 2 ) or -CH 2 -C(0)-
- R 1 and R 2 are each independently selected from the group consisting of hydrogen, L 1 , Cy 1 , and -L 1 -Cy 1 .
- R 1 and/or R 2 is hydrogen.
- R 1 and/or R 2 is alkyl or alkenyl, preferably allyl.
- R 1 and/or R 2 is aryl, heteroaryl, aralkyl, or heteroaralkyl, the rings of each of which optionally is substituted and optionally is fused to one or more aryl rings .
- aryl , heteroaryl , aralkyl , and heteroaralkyl groups comprise a phenyl, pyridyl, or pyrrolyl ring.
- R 1 and/or R 2 is cycloalkyl, e.g. , cyclopropyl, cyclopentyl, or cyclohexyl, which optionally is substituted and optionally is fused to one or more aryl rings .
- R 3 and R 4 are each independently selected from the group consisting of hydrogen, L 1 , Cy 1 , and -L 1 -Cy 1 .
- R 3 and/or R 4 is hydrogen.
- R 3 and/or R 4 is alkyl or alkenyl, preferably allyl.
- R 3 and/or R 4 is aryl, heteroaryl, aralkyl, or heteroaralkyl, the rings of each of which optionally is substituted and optionally is fused to one or more aryl rings.
- aryl, heteroaryl, aralkyl, and heteroaralkyl groups comprise a phenyl, pyridyl, or pyrrolyl ring.
- R 3 and/or R 4 is cycloalkyl, e.g., cyclopropyl, cyclopentyl, or cyclohexyl, which optionally is substituted and optionally is fused to one or more aryl rings.
- L 1 is C ⁇ -C 3 alkyl, C 2 -C 6 heteroalkyl, or C 3 -
- L 1 is not a terminal group, then L 1 is C!-C 6 alkylene, C-C 6 heteroalkylene, or C 3 -C 3 alkenylene.
- L 1 is alkylene, preferably methylene or ethylene.
- L 1 is alkenyl, preferably allyl.
- Cy 1 is the radical of a heterocyclic group including, without limitation, piperidine, pyrrolidine, piperazine, and morpholine, each ' of which optionally is substituted and optionally is fused to one or more aryl rings.
- Cy 1 is cycloalkyl, e.g., cyclopropyl, cyclopentyl, or cyclohexyl.
- Cy 1 is aryl or heteroaryl, e.g., phenyl, pyridyl, or pyrrolyl, each of which optionally is substituted and optionally is fused to one or more aryl rings . In some embodiments, Cy 1 is fused to one or two benzene rings. In some embodiments, Cy 1 has between one and about five substituents selected from the group consisting of C-C 4 alkyl, C 3. -C 4 alkoxy, and halo. Examples of preferred substituents include methyl, methoxy, and fluoro.
- R 1 and R 2 and/or R 3 and R 4 are taken together with the adjacent nitrogen atom to form a 5- or 6-membered ring, wherein the ring atoms are independently selected from the group consisting of C, 0, and N, and wherein the ring optionally is substituted, and optionally is fused to one or more aryl rings.
- R 1 and R 2 and/or R 3 and R 4 are taken together with the adjacent nitrogen atom to form a ring such as, for example, pyrrolidine, piperidine, piperazine, and morpholine, wherein the ring optionally is substituted, and optionally is fused to an aryl ring.
- the ring comprising R 1 and R 2 or R 3 and R 4 is fused to a benzene ring.
- the ring comprising R 1 and R 2 or R 3 and R 4 has a substituent comprising an aryl or cycloalkyl ring, either of which optionally is substituted and optionally is fused to a cycloalkyl, aryl, heteroaryl, or heterocyclic ring.
- Preferred substituents include, without limitation, phenyl, phenylmethyl , and phenylethyl, the phenyl ring of which optionally is fused to a cycloalkyl, aryl, or heterocyclic ring.
- the HDAC inhibitors of the invention comprise compounds of formula 1(a):
- J is Cx-C a -hydrocarbyl, -N(R 20 )-, -N(R 20 ) -CH 2 -, -0-, or -0-CH 2
- R 20 is -H or -Me
- X and Y are independently selected from -NH 2 , cycloalkyl, heterocyclyl, aryl, heteroaryl, and A- (C 1 -C 3 -alkyl) n -B-;
- A is H, Ci-Cg-alkyloxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl;
- B is -NH-, -0-, or a direct bond; and n is 0 (in which case A is directly bonded to B) or 1.
- A is phenyl optionally substituted with one or more moieties selected from halo (preferably chloro) and methoxy, and B is -NH- .
- A is selected from cyclopropyl, pyridinyl, and indanyl .
- R 20 is -H.
- X is preferably selected from
- Y is preferably selected from
- the HDAC inhibitors of the invention comprise the following compounds of formula la:
- novel histone deacetylase inhibitors of the invention are represented by formula (2) :
- Cy 2 is cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is optionally substituted and each of which is optionally fused to one or more aryl or heteroaryl rings, or to one or more saturated or partially unsaturated cycloalkyl or heterocyclic rings, each of which rings is optionally substituted;
- X 1 is selected from the group consisting of a covalent bond, M 1 - L 2 -M ⁇ and L 2 -M 2 -L 2 wherein
- L 2 at each occurrence, is independently selected from the group consisting of a chemical bond, C 0 -C 4 hydrocarbyl, C 0 -C 4 - hydrocarbyl- (NH) -C 0 -C 4 -hydrocarbyl, C 0 -C 4 -hydrocarbyl- (S) -C 0 -C 4 - hydrocarbyl, and C 0 -C 4 -hydrocarbyl- (O) -C 0 -C 4 -hydrocarbyl, provided that L 2 is not a chemical bond when X 1 is M 1 -L 2 -M 1 ;
- M 1 at each occurrence, is independently selected from the group consisting of -0-, -N(R 7 )-, -S-, -S(O)-, S(0) 2 -, - S(0) 2 N(R 7 )-, -N(R 7 )-S(0) 2 -, -C(0)-, -C(0)-NH-, -NH-C(O)-, -NH-C(O) -0--and -0-C(0)-NH-, wherein R 7 is selected from the group consisting of hydrogen, alkyl, aryl, aralkyl, acyl, heterocyclyl, and heteroaryl; and
- M 2 is selected from the group consisting of M 1 , heteroarylene, and heterocyclylene, either of which rings optionally is substituted;
- Ar 2 is arylene or heteroarylene, each of which is optionally substituted;
- R s and R 6 are independently selected from the group consisting of hydrogen, alkyl, aryl, and aralkyl; q is 0 or 1; and
- Ay 2 is a 5-6 membered cycloalkyl, heterocyclyl, or heteroaryl substituted with an amino or hydroxy moiety (preferably these groups are ortho to the amide nitrogen to which Ay 2 is attached) and further optionally substituted; provided that when Cy 2 is naphthyl, X 1 is -CH 2 -, Ar 2 is phenyl, R 5 and R 6 are H, and q is 0 or 1, Ay 2 is not phenyl or o-hydroxyphenyl .
- X 1 is C 0 -C 8 -alkyl-X la - C 0 -C 8 -alkyl, wherein X la is -CH 2 -, -0-, -S-, -NH- , - C(O)-, then Cy 2 is not optionally substituted naphthyl or di- or - tetrahydronaphthalene .
- Ay 2 is phenyl or thienyl, each substituted with -OH or -NH 2 .
- Ay 2 is optionally amino- or hydroxy-substituted phenyl or thienyl, wherein the amino or hydroxy substituent is preferably ortho to the nitrogen to which Ay 2 is attached. [0067] More preferably in the compounds according to paragraph [0058] , Ay 2 is ortho aniline, ortho phenol, 3-amino-2-thienyl, or 3- hydroxy-2-thienyl, and tautomers thereof.
- novel histone deacetylase inhibitors of the invention are those according to paragraph [0058] wherein q is 1;
- M 1 at each occurrence, is selected from the group consisting of -N(R 7 )-, -S-, -C(0)-NH-, and -0-C(0)-NH-, where R 7 is selected from the group consisting of hydrogen, alkyl, aryl, aralkyl, and acyl; and
- Ay 2 is anilinyl, which optionally is substituted.
- the -NH 2 group of Ay 2 is in an ortho position with respect to the nitrogen atom to which Ay 2 is attached.
- R 5 and R 6 are independently selected from the group consisting of ,hydrogen and C x -C 4 alkyl. In some preferred embodiments, R 5 and R 6 are hydrogen.
- Ar 2 has the formula
- Ar 2 has the formula
- Ar 2 is selected from the group consisting of phenylene, pyridylene, pyrimidylene, and quinolylene.
- X 1 is a chemical bond.
- X 1 is L 2 -M 2 -L 2
- M 2 is selected from the group consisting of -NH-, -N(CH 3 )-, -S-, -C(0)-N(H)-, and -0-C (O) -N(H) - .
- X 1 is L-M 2 -L 2 , where at least one occurrence of L 2 is a chemical bond. In other embodiments, X 1 is L 2 -M 2 -L 2 , where at least one occurrence of L 2 is alkylene, preferably methylene. In still other embodiments, X 1 is L 2 - M 2 -L 2 , where at least one occurrence of L 2 is alkenylene. In some embodiments, X 1 is M 1 -L 2 -M 1 and M 1 is selected from the group consisting of -NH-, -N(CH 3 )-, -S-, and -C(0)-N(H)-.
- Cy 2 is aryl or heteroaryl, e.g., phenyl, pyridyl, imidazolyl, or quinolyl, each of which optionally is substituted.
- Cy 2 is heterocyclyl, e.g.,
- Cy 2 has from one and three substituents independently selected from the group consisting of alkyl, alkoxy, amino, nitro, halo, haloalkyl, and haloalkoxy.
- substituents include methyl, methoxy, fluoro, trifluoromethyl, trifluoromethoxy, nitro, amino, aminomethyl, and hydroxymethyl .
- the invention comprises compounds of structural formula (2a) :
- Ar is phenyl or thienyl
- R 6 is H, or C ⁇ -C 6 -alkyl (preferably --CH 3 ) ;
- W is halo, (V -L 4 ) t -V-L 3 -;
- L 3 is a direct bond, -C ⁇ -C 6 -hydrocarbyl, -(C x -C 3 -hydrocarbyl ) m ⁇ -
- 'ml and m2 are independently 0 or 1;
- X' is -N(R 21 )-, -C(0)N(R 21 ) -, N(R 21 )C(0)-, -0-, or -S-;
- R 21 is -H, V"- (Ci-C 6 -hydrocarbyl) c ;
- L 4 is (C ⁇ -C 3 -hydrocarbyl) a -M- (C x -C 3 -hydrocarbyl) b ;
- a and b are independently 0 or 1;
- M is -NH-, -NHC(O)-, -C(0)NH-, -C(O)- ⁇ SO 2 ⁇ i -NHS0 2 -, or S0 2 NH-
- V, V, and V" are independently selected from cycloalkyl, heterocyclyl, aryl, and heteroaryl; -
- .t is 0 or 1; or W, the annular C to which it is bound, and Y together form a monocyclic cycloalkyl, heterocyclyl, aryl, or heteroaryl; and wherein the A and Ar a rings are optionally further substituted with from 1 to 3 substituents independently selected from methyl, hydroxy, methoxy, halo, and amino.
- L 3 is -NH-CH- or -CH-NH-;
- V is phenyl optionally substituted with from 1 to 3 moieties independently selected from halo, hydroxy, C x -C 6 -hydrocarbyl, C ⁇ ⁇ C 6 -hydrocarbyl-oxy or -thio (particularly methoxy or methylthio) , wherein each of the hydrocarbyl moieties are optionally substituted with one or more moieties independently selected from halo, nitroso, amino, sulfonamido, and cyano; and Ar is phenyl and the amino moieties to which it is bound are ortho to each other.
- V is an optionally substituted ring moiety selected from:
- W is selected from: ,
- the A and Ar a rings are not further substituted.
- the compounds of the invention are selected from the following, in which, unless expressly displayed otherwise, Ar a is phenyl (and, preferably, the amide nitrogen and the amino nitrogen bound to Ar are ortho to each other) :
- the compounds of the invention comprise compounds of the formula (2b) :
- Ay 2 is phenyl or thienyl, each substituted at the ortho position with -NH 2 or -OH and each further optionally substituted with one to three substituents independently selected from -NH 2 , -OH, and halo; q is 0 or 1; X 1 is selected from -CH 2 -, -NH-CH 2 -, ⁇ and -S-CH 2 -;
- Cy 2 is monocyclic or fused bicyclic aryl or heteroaryl optionally substituted with one to three substituents selected from CH 3 -, CH 3 0-, phenyl optionally substituted with one to three CH 3 0-, morphylinyl, morphylinyl-C 1 -C 3 -alkoxy, cyano, and CH 3 C(0)NH-; provided that when Cy 2 is naphthyl, X 1 is -CH 2 -, and q is 0 or 1, Ay 2 is not o-hydroxyphenyl .
- Ay 2 is selected from:
- Cy 2 is phenyl, pyridinyl, pyrimidinyl, benzimidazolyl, benzothiazolyl, thienyl, tetrahydroquinozolinyl, or 1, 3-dihydroquinazoline-2, 4-dione, each optionally substituted with one to three CH 3 0- . More preferably, Cy 2 is phenyl substituted with one to three CH 3 0- .
- the novel inhibitors of histone deacetylase are represented by formula (3) :
- Ar 3 is arylene or heteroarylene, either of which optionally is substituted;
- Cy 3 is cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which optionally is substituted, and each of which optionally is fused to one or more aryl or heteroaryl rings, or to one or more saturated or partially unsaturated cycloalkyl or heterocyclic rings, each of which rings optionally is substituted; provided that ' when Cy 3 is a cyclic moiety having -C(0)-, -C(S)-, -S(O)-, or -S(0) 2 - in the ring, then Cy 3 is not additionally substituted with a group comprising an aryl or heteroaryl ring; and
- X 2 is selected from the group consisting of a chemical bond, L 3 , W x -L 3 , wherein 1 , at each occurrence, is S, 0, or N(R 9 ) , where R 9 is selected from the group consisting of hydrogen, alkyl, aryl, and aralkyl ; and
- L 3 is C1-C4 alkylene, C 2 -C 4 alkenylene, or C 2 -C 4 alkynylene; provided that X 2 does not comprise a -C(O)-, -C(S)-, -S(0)-, or -S(0) 2 - group; and further provided that when Cy 3 is pyridine, then X 2 is L 3 , Vl 1 -!/ , or L 3 -W ⁇ [0084]
- Ar 3 has the structure:
- X 2 is selected from the group consisting of L 3 ,, W 1 -!. 3 , L 3 - 1 , 1 -L 3 - 1 , and L 3 - x -L 3 .
- Cy 3 is not the radical of a substituted or unsubstituted diazepine or benzofuran.
- Q at each occurrence is C(R 8 ), where R 8 is selected from the group consisting of hydrogen, alkyl, aryl, aralkyl, alkoxy, amino, nitro, halo, haloalkyl, and haloalkoxy. In some other embodiments, from one to about three variables Q are nitrogen.
- Ar 3 is selected from the group consisting of phenylene, pyridylene, thiazolylene, and quinolylene .
- X 2 is a chemical bond. In other embodiments, X 2 is a non- cyclic hydrocarbyl. In some such embodiments, X 2 is alkylene, preferably methylene or ethylene. In other such embodiments, X 2 is alkenylene or alkynylene. In still other such embodiments, one carbon in the hydrocaryl chain is replaced with -NH- or -S-. In some preferred embodiments, X 2 is ⁇ - 1 and 1 is -NH- or -N(CH 3 )-. [0089] In some embodiments of the compounds according to paragraph [0083], Cy 3 is cycloalkyl, preferably cyclohexyl.
- Cy 3 is aryl or heteroaryl, e.g. , phenyl, pyridyl, pyrimidyl, imidazolyl, thiazolyl, oxadiazolyl, quinolyl, or fluorenyl, each of which optionally is substituted and optionally is fused to one or more aryl rings.
- the cyclic moiety of Cy 3 is fused to a benzene ring.
- Cy 3 has from one to three substituents independently selected from the group consisting of alkyl, alkoxy, aryl, aralkyl, amino, halo, haloalkyl, and hydroxyalkyl.
- substituents examples include methyl, methoxy, fluoro, trifluoromethyl, amino, nitro, aminomethyl, hydroxymethyl , and phenyl.
- Some other preferred substituents have the formula -K 1 -N(H) (R 10 ) , wherein
- K 1 is a chemical bond or C ⁇ -C 4 alkylene
- R 10 is selected from the group consisting of Z' and -Ak 2 -Z' , wherein
- Ak 2 is C ⁇ -C 4 alkylene
- Z' is cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which optionally is substituted, and each of which optionally is fused to one or more aryl or heteroaryl rings, or to one or more saturated or partially unsaturated cycloalkyl or heterocyclic rings .
- Cy 3 is heterocyclyl, e. g. ,
- the heterocycle of Cy 3 is fused to a benzene ring.
- X is -CH 2 -, -NH-, 0, or S .
- Ar 3 is
- novel histone deacetylase inhibitors of the invention are those according to paragraph [0058] wherein
- Ay 2 is ortho-anilinyl; q is 0 ; and
- X 1 is M ⁇ - 1 or L 2 -M 2 -L 2 .
- a 7 -L 7 -B 7 - wherein A 7 is an optionally substituted heteroaryl or optionally substituted heterocyclyl; wherein L 7 is a covalent bond; and wherein B 7 is -CH 2 -; j) aptionally substituted heteroaryl or optionally substituted heterocyclyl ; k) A 8 L 8 -B 8 -, wherein A 8 is optionally substituted phenyl; wherein
- L 8 is a covalent bond; and wherein B 8 is -0- ; 1) Ag-Lg-Bg-, wherein A 9 is an optionally substituted aryl; wherein L 9 is a covalent bond; and wherein B 9 is a furan group ; m) A ⁇ 0 -L 10 -B ⁇ 0 - , wherein A i0 is an optionally substituted heteroaryl or optionally substituted heterocyclyl; wherein L 10 is -
- B 10 is -NHCH 2 -; • n) An-Ln-Bn- , wherein An is an optionally substituted heteroaryl or optionally substituted heterocyclyl; wherein u is a covalent bond; and wherein B X1 is -0CH 2 -; o) A 12 -L i2 -B ⁇ 2 -, wherein A i2 is an optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl; wherein L i2 is-NHC(O)-; and wherein B i2 is -
- N (optionally substituted aryl)CH 2 -; p) A ⁇ 3 -L 13 -B ⁇ 3 - , wherein A i2 is an optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl; wherein L i3 is a covalent bond; and wherein B i3 is -NHC(0) -; q) Ai 4 -L 14 -Bi 4 -, wherein A i4 is an optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl; wherein L 14 is-NHC(O) (optionally substituted heteroaryl); and wherein, B ⁇ 4 is -S-S-; r) F 3 CC(0)NH- ; s) Ai 5 -L is -Bi 5 -, wherein A l5 is an optionally substituted aryl, optionally substituted.
- L i5 is- (CH 2 ) 0 - ⁇ NH (optionally substituted heteroaryl)-; and wherein B 15 is -NHCH 2 -; t) Ai 6 - 16 -B ⁇ S -, wherein A 16 is an optionally substituted aryl, .
- optionally substituted heteroaryl or optionally substituted heterocyclyl wherein L 16 is a covalent bond; and wherein B 16 is - (optionally substituted alkyl) CH 2 -; and u) A ⁇ 6 -L ⁇ 6 -Bi 6 - , wherein A 16 is an optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl; wherein L 16 is a covalent bond; and wherein B 16 is -(optionally substituted aryl-CH 2 ) 2 -N- .
- Cy 2 -X 1 - is collectively selected from the group consisting of a) Di-Ei-F- , wherein D x is an optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl; wherein E x is -CH 2 - or a covalent bond; and wherein B x is a covalent bond; b) D 2 -E 2 -F 2 -, wherein D 2 is an optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl; wherein E 2 is -NH (CH 2 ) 0 _ 2 -; and wherein F 2 is a covalent bond; c) D 3 -E 3 -F 3 -, wherein D 3 is an optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl; wherein E 3 is - (CH 2 ) 0
- Y and Z are independently N or CH and is selected from the group consisting of:
- the compounds comprise those wherein Y, Z and W are as defined below:
- the compounds comprise those wherein Y, Z and W are as defined below:
- novel histone deacetylase inhibitors of the invention are selected from the group consisting of the following and their pharmaceutically acceptable salts:
- the compounds are selected from those listed in Tables 2a-b, 3a-d, 4a-c, and 5a-5f .
- dlchloroaminotriazine III may be reacted with ammonia gas in 1,4 dioxane to produce diaminochlorotriazine IV.
- Treatment of IV with R ⁇ NH in THF or 1,4 dioxane in a sealed flask then affords triaminotriazine VI .
- the chloride of XI is converted to the anilinyl amide of XII as described above with respect to Scheme 1: treatment with the amine and diisopropylethylamine; followed by lithium hydroxide; followed by BOP reagent, phenylenediamine, triethylamine, and DMF.
- compounds of formula (2) wherein X 1 comprises -N(R 7 )-, may be prepared according to the synthetic route depicted in Scheme 6.
- Carboxylic acid XXXV in methanol is treated with hydrochloric acid to produce ester XXXVI.
- Conversion of the primary amine moiety in XXXVI to the secondary amine moiety in XXXVI is effected by treatment with a catalyst such as triethylamine, methoxybenzylchloride, sodium iodide, and potassium carbonate in DMF at 60 °C.
- Ester XXXVI is converted to anilinyl amide XXXVII by treatment with sodium hydroxide, THF, and methanol, followed by BOP, triethylamine, and phenylenediamine in DMF, as described above for Scheme 3.
- Compounds such as XLVII and XLIX preferably may be prepared as outlined in Scheme 8. Dibromopyridine is combined with diaminoethane to produce amine XLIV. Treatment of amine XLIV with isatoic anhydride LV in methanol and water, followed by refluxing in formic acid affords compound XLVI . Treatment of amine XLIV with the reaction products of benzylaminodiacetic acid and acetic anhydride provides compound XLVIII .
- Bromopyridylamines XLVI and XLVIII are then converted to the corresponding diene anilinylamides XLVII and XLIX, respectively, by procedures analogous to those set forth in Schemes 3-7 above.
- Compounds such as LIV preferably may be prepared according to the synthetic route depicted in Scheme 9. Trichlorotriazine is treated with aminoindan and diisopropylethylamine to produce dlchloroaminotriazine L. Treatment with bromobenzylamine and diisopropylethylamine affords diaminochlorotriazine LI . Addition of ammonia gas and dioxane provides triaminotriazine LII .
- Dihydroxyquinoline LV with dimethylaminopyridine (DMAP) in pyridine is treated with trifluoromethanesulfonic anhydride to provide bis (trifluoromethanesulfonyloxy) -quinoline LVI .
- Treatment of LVI with p-methoxybenzylamine affords aminoquinoline LVII.
- Anilinyl amides LVIII and LIX are then prepared using procedures analogous to those described for Schemes 1-9 above.
- ester LXI may be treated with chloroethylmorphonline, sodium iodide, potassium carbonate, triethylamine, and tetrabutylammonium iodide (TBAI) in DMF to produce ester LXIII, which is then converted to acid LXIV as in Scheme 1.
- Conversion of the acid LXIV to the anilinyl amide LXV is effected by procedures analogous to those set forth in Scheme 1 above.
- Compounds such as C preferably may be prepared as outlined in Scheme 20.
- Alylamine XCVII is treated with thiocarbonyl diimidazole in dichloromethane, follwed by ammonium hydroxide to afford thiourea XCVIII .
- Treatment of thiourea XCVIII with methylmethoxyacrylate in dioxane and N-bromosuccinimide produces thiazole ester IC.
- the ester IC is converted to the corresponding anilinylamine C using procedures analogous to those set forth in Scheme 1 above.
- Compounds such as CVIII preferably may be prepared according to the synthetic route depicted in Scheme 24. Dlchloroaminotriazine CVI is treated with methyl-4-aminobenzoate in the presence of diisopropylethylamine to produce diaminotriazine CVII . Addition of ammonia gas and dioxane, followed by a saponification and a peptide coupling using the same procedures analogous to those described for Scheme 1 above.
- Compounds such as CX preferably may be prepared according to the synthetic route depicted in Scheme 30.
- the Grignard reaction of trichloroaminotriazine with various alkyl magnesium bromide, followed by a treatment with methyl-4-aminobenzoate in the presence of diisopropylethylamine yields alkylaminotriazine CIX.
- Synthetic methods similar to those set forth in Scheme 1 above are then used to convert ester CIX to the corresponding anilinyl amide CX.
- Compounds such as CXVIII preferably may be prepared according to the synthetic route depicted in Scheme 33.
- Treatment of methoxyaminobenzothiazole with tribromide boron affords the corresponding acid CXV.
- Mitsunobu reaction using hydroxyethyl morpholine in the presence of diethylazodicarboxylate and triphenylphosphine yields the amine CXVI.
- Reductive amination with methyl-4-formylbenzoate using phenylsilane and tin catalyst yields to the ester CXVII.
- Saponification followed by the usual peptide coupling analogous to those describe for Scheme 1 above provides the desired anilide CXVIII.
- Compounds such as CXXIII and CXXVII preferably may be prepared according to the synthetic scheme 49. Consecutive treatment of acetyl acetone with methyl bromomethylbenzoate in the presence of NaOMe and phenyl hydrazine followed by saponification, afforded the intermediate acid CXXII. This material was coupled with 1,2-diaminobenzene in a standard fashion to afford CXXIII .
- Compounds such as CXXX preferably may be prepared according to the synthetic scheme 50.
- Treatment of 4-cyanomethylbenzoic acid with hydroxylamine produced the amidoxime CXXVIII, which upon treatment with acetic anhydride was converted into the oxadiazole CXXIX.
- the latter was coupled with 1,2-diaminobenzene in a standard fashion to afford CXXX.
- Compounds such as CXXXIII preferably may be prepared according to the synthetic route depicted in Scheme 57.
- Treatment of 4- formylbenzoic acid with thionyl chloride afford the acyl chloride which is coupled with protected anilide to produce CXXXI.
- Reductive amination with dimethoxyaniline using phenylsilane and tin catalyst yields to the protected anilide CXXXII.
- Treatment with isocyanate followed by deprotection with trifluoroacetic acid provides the ureidoanilide CXXXIII.
- compositions comprising an inhibitor of histone deacetylase according to the invention and a pharmaceutically acceptable carrier, excipient, or diluent.
- Compounds of the invention may be formulated by any method well known in the art and may be prepared for administration by any route, including, without limitation, parenteral, oral, sublingual, transdermal, topical, intranasal, intratracheal, or intrarectal .
- compounds of the invention are administered intravenously in a hospital setting.
- administration may preferably be by the oral route .
- compositions according to the invention may contain, in addition to the inhibitor, diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art.
- diluents fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art.
- the preparation of pharmaceutically acceptable formulations is described in, e.g., Remington's Pharmaceutical Sciences, 18th Edition, ed. A. Gennaro, Mack Publishing Co., Easton, PA, 1990.
- salts refers to salts that retain the desired biological activity of the above-identified compounds and exhibit minimal or no undesired toxicological effects.
- examples of such salts include, but are not limited to acid addition salts formed with inorganic acids (for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like) , and salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid, and polygalacturonic acid.
- inorganic acids for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like
- organic acids such as acetic acid, oxalic acid, tartaric acid, succ
- the compounds can also be administered as pharmaceutically acceptable quaternary salts known by those skilled in the art, which specifically include the quaternary ammonium salt of the formula -NR + Z-, wherein R is hydrogen, alkyl, or benzyl, and Z is a counterion, including chloride, bromide, iodide, -O-alkyl, toluenesulfonate, methylsulfonate, sulfonate, phosphate, or carboxylate
- the active compound is included in the pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to a patient a therapeutically effective amount without causing serious toxic effects in the patient treated.
- a preferred dose of the active compound for all of the above-mentioned conditions is in the range from about 0.01 to 300 mg/kg, preferably 0.1 to 100 mg/kg per day, more generally 0.5 to about 25 mg per kilogram body weight of the recipient per day.
- a typical topical dosage will range from 0.01-3% wt/wt in a suitable carrier.
- the effective dosage range of the pharmaceutically acceptable derivatives can be calculated based on the weight of the parent compound to be delivered. If the derivative exhibits activity in itself, the effective dosage can be estimated as above using the weight of the derivative, or by other means known to those skilled in the art.
- the invention provides a method of inhibiting histone deacetylase in a cell, comprising contacting a cell in which inhibition of histone deacetylase is desired with an inhibitor of histone deacetylase according to the invention. Because compounds of the invention inhibit histone deacetylase, they are useful research tools for in vitro study of the role of histone deacetylase in biological processes . In addition, the compounds of the invention selectively inhibit certain isoforms of HDAC.
- Measurement of the enzymatic activity of a histone deacetylase can be achieved using known methodologies. For example, Yoshida et al . , J. Biol. Chem., 265: 17174-17179 (1990), describes the assessment of histone deacetylase enzymatic activity by the detection of acetylated histones in trichostatin A treated cells. Taunton et al . , Science, 272 : 408-411 (1996) , similarly describes methods to measure histone deacetylase enzymatic activity using endogenous and recombinant HDAC-1.
- the histone deacetylase inhibitor interacts with and reduces the activity of all histone deacetylases in the cell. In some other preferred embodiments according to this aspect of the invention, the histone deacetylase inhibitor interacts with and reduces the activity of fewer than all histone deacetylases in the cell. In certain preferred embodiments, the inhibitor interacts with and reduces the activity of one histone deacetylase (e.g., HDAC-1), but does not interact with or reduce the activities of other histone deacetylases
- one histone deacetylase e.g., HDAC-1
- histone deacetylase inhibitors are those that interact with, and reduce the enzymatic activity of, a histone deacetylase that is involved in tumorigenesis .
- Certain other preferred histone deacetylase inhibitors interact with and reduce the enzymatic activity of a fungal histone deacetylase.
- the method according to the third aspect of the invention causes an inhibition of cell proliferation of the contacted cells.
- the phrase "inhibiting cell proliferation” is used to denote an ability of an inhibitor of histone deacetylase to retard the growth of cells contacted with the inhibitor as compared to cells not contacted.
- An assessment of cell proliferation can be made by counting contacted and non-contacted cells using a Coulter Cell Counter (Coulter, Miami, FL) or a hemacytometer . Where the cells are in a solid growth (e.g., a solid tumor or organ) , such an assessment of cell proliferation can be made by measuring the growth with calipers and comparing the size of the growth of contacted cells with non-contacted cells.
- growth of cells contacted with the inhibitor is retarded by at least 50% as compared to growth of non-contacted cells. More preferably, cell proliferation is inhibited by 100% (i.e., the contacted cells do not increase in number) . Most preferably, the phrase "inhibiting cell proliferation" includes a reduction in the number or size of contacted cells, as compared to non-contacted cells.
- an inhibitor of histone deacetylase according to the invention that inhibits cell proliferation in a contacted cell may induce the contacted cell to undergo growth retardation, to undergo growth arrest, to undergo programmed cell death (i.e., to apoptose) , or to undergo necrotic cell death.
- the cell proliferation inhibiting ability of the histone deacetylase inhibitors according to the invention allows the synchronization of a population of asynchronously growing cells.
- the histone deacetylase inhibitors of the invention may be used to arrest a population of non-neoplastic cells grown in vitro in the Gl or G2 phase of the cell cycle.
- Such synchronization allows, for example, the identification of gene and/or gene products expressed during the Gl or G2 phase of the cell cycle.
- Such synchronization of cultured cells may also be useful for testing the efficacy of a new transfection protocol, where transfection efficiency varies and is dependent upon the particular cell cycle phase of the cell to be transfected.
- Use of the histone deacetylase inhibitors of the invention allows the synchronization of a population of cells, thereby aiding detection of enhanced transfection efficiency.
- the contacted cell is a neoplastic cell.
- neoplastic cell is used to denote a cell that shows aberrant cell growth.
- the aberrant cell growth of a neoplastic cell is increased cell growth.
- a neoplastic cell may be a hyperplastic cell, a cell that shows a lack of contact inhibition of growth in vitro, a benign tumor cell that is incapable of metastasis in vivo, or a cancer cell that is capable of metastasis in vivo and that may recur after attempted removal.
- tumorgenesis is used to denote the induction of cell proliferation that leads to the development of a neoplastic growth.
- the histone deacetylase inhibitor induces cell differentiation in the contacted cell.
- a neoplastic cell when contacted with an inhibitor of histone deacetylase may be induced to differentiate, resulting in the production of a non- neoplastic daughter cell that is phylogenetically more advanced than the contacted cell.
- the contacted cell is in an animal.
- the invention provides a method for treating a cell proliferative disease or condition in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a histone deacetylase inhibitor of the invention.
- the animal is a mammal, more preferably a domesticated mammal. Most preferably, the animal is a human.
- cell proliferative disease or condition is meant to refer to any condition characterized by aberrant cell growth, preferably abnormally increased cellular proliferation.
- cell proliferative diseases or conditions include, but are not limited to, cancer, restenosis, and psoriasis.
- the invention provides a method for inhibiting neoplastic cell proliferation in an animal comprising administering to an animal having at least one neoplastic cell present in its body a therapeutically effective amount of a histone deacetylase inhibitor of the invention.
- the invention also provides a method for treating or preventing a protozoal disease or infection, comprising administering to an animal in need of such treatment a therapeutically effective amount of a histone deacetylase inhibitor of the invention.
- the animal is a mammal, more preferably a human.
- the histone deacetylase inhibitor used according to this embodiment of the invention inhibits a protozoal histone deacetylase to a greater extent than it inhibits mammalian histone deacetylases, particularly human histone deacetylases .
- the present invention further provides a method for treating a fungal disease or infection comprising administering to an animal in need of such treatment a therapeutically effective amount of a histone deacetylase inhibitor of the invention.
- the animal is a mammal, more preferably a human.
- the histone deacetylase inhibitor used according to this embodiment of the invention inhibits a fungal histone deacetylase to a greater extent than it inhibits mammalian histone deacetylases, particularly human histone deacetylases.
- terapéuticaally effective amount is meant to denote a dosage sufficient to cause inhibition of histone deacetylase activity in the cells of the subject, or a dosage sufficient to inhibit cell proliferation or to induce cell differentiation in the subject.
- Administration may be by any route, including, without limitation, parenteral, oral, sublingual, transdermal, topical, intranasal, intratracheal, or intrarectal .
- compounds of the invention are administered intravenously in a hospital setting.
- administration may preferably be by the oral route.
- the histone deacetylase inhibitor is preferably administered at a sufficient dosage to attain a blood level of the inhibitor from about 0.01 ⁇ M to about 100 ⁇ M, more preferably from about 0.05 ⁇ M to about 50 ⁇ M, still more preferably from about 0.1 ⁇ M to about 25 ⁇ M, and still yet more preferably from about 0.5 ⁇ M to about 25 ⁇ M.
- concentrations typically be effective, and much higher concentrations may be tolerated.
- the dosage of histone deacetylase inhibitor necessary to produce a therapeutic effect may vary considerably depending on the tissue, organ, or the particular animal or patient to be treated.
- the method further comprises contacting the cell with an antisense oligonucleotide that inhibits the expression of a histone deacetylase.
- an antisense oligonucleotide that inhibits the expression of a histone deacetylase.
- a nucleic acid level inhibitor e.g., antisense oligonucleotide
- a protein level inhibitor i.e., inhibitor of histone deacetylase enzyme activity
- the antisense oligonucleotides according to this aspect of the invention are complementary to regions of RNA or double-stranded DNA that encode HDAC- 1, HDAC-2, HDAC-3, HDAC-4, HDAC-5, HDAC-6, HDAC7 , and/or HDAC-8 (see e.g., GenBank Accession Number U50079 for HDAC-1, GenBank Accession Number U31814 for HDAC-2, and GenBank Accession Number U75697- for HD A C- 3) .
- oligonucleotide includes polymers of two or more deoxyribonucleosides, ribonucleosides, or 2' -substituted ribonucleoside residues, or any combination thereof.
- oligonucleotides Preferably, such oligonucleotides have from about 6 to about 100 nucleoside residues, more preferably from about 8 to about 50 nucleoside residues, and most preferably from about 12 to about 30 nucleoside residues.
- the nucleoside residues may be coupled to each other by any of the numerous known internucleoside linkages.
- internucleoside linkages include without limitation phosphorothioate, phosphorodithioate, alkylphosphonate, alkylphosphonothioate, phosphotriester, phosphoramidate, siloxane, carbonate, carboxymethylester, acetamidate, carbamate, thioether, bridged phosphoramidate, bridged methylene phosphonate, bridged phosphorothioate and sulfone internucleoside linkages.
- these internucleoside linkages may be phosphodiester, phosphotriester, phosphorothioate, or phosphoramidate linkages, or combinations thereof.
- the term oligonucleotide also encompasses such polymers having chemically modified bases or sugars and/ or having additional substituents, including without limitation lipophilic groups, intercalating agents, diamines and adamantane .
- the term "2' -substituted ribonucleoside” includes ribonucleosides in which the hydroxyl group at the 2' position of the pentose moiety is substituted to produce a 2'-0- substituted ribonucleoside.
- substitution is with a lower alkyl group containing 1-6 saturated or unsaturated carbon atoms, or with an aryl or allyl group having 2-6 carbon atoms, wherein such alkyl, aryl or allyl group may be unsubstituted or may be substituted, e.g., with halo, hydroxy, trifluoromethyl, cyano, nitro, acyl, acyloxy, alkoxy, carboxyl, carbalkoxyl, or amino groups.
- the term "2'- substituted ribonucleoside” also includes ribonucleosides in which the 2 ' -hydroxyl group is replaced with an amino group or with a halo group, preferably fluoro .
- Particularly preferred antisense oligonucleotides utilized in this aspect of the invention include chimeric oligonucleotides and hybrid oligonucleotides .
- a "chimeric oligonucleotide” refers to an oligonucleotide having more than one type of internucleoside linkage.
- a chimeric oligonucleotide is a chimeric oligonucleotide comprising a phosphorothioate, phosphodiester or phosphorodithioate region, preferably comprising from about 2 to about 12 nucleotides, and an alkylphosphonate or alkylphosphonothioate region (see e.g., Pederson et al. U.S. Patent Nos. 5,635,377 and 5,366,878).
- such chimeric oligonucleotides contain at least three consecutive internucleoside linkages selected from phosphodiester and phosphorothioate linkages, or combinations thereof.
- hybrid oligonucleotide refers to an oligonucleotide having more than one type of nucleoside.
- One preferred example of such a hybrid oligonucleotide comprises a ribonucleotide or 2' -substituted ribonucleotide region, preferably comprising from about 2 to about 12 2' -substituted nucleotides, and a deoxyribonucleotide region.
- such a hybrid oligonucleotide contains at least three consecutive deoxyribonucleosides and also contains ribonucleosides, 2' -substituted ribonucleosides, preferably 2 ' - O-substituted ribonucleosides, or combinations thereof (see e.g., Metelev and Agrawal, U.S. Patent No. 5,652,355).
- nucleotide sequence and chemical structure of an antisense oligonucleotide utilized in the invention can be varied, so long as the oligonucleotide retains its ability to inhibit expression of the gene of interest. This is readily determined by testing whether the particular antisense oligonucleotide is active.
- Useful assays for this purpose include quantitating the mRNA encoding a product of the gene, a Western blotting analysis assay for the product of the gene, an activity assay for an enzymatically active gene product, or a soft agar growth assay, or a reporter gene construct assay, or an in vivo tumor growth assay, all of which are described in detail in this specification or in Ramchandani et al . (1997) Proc. Natl. Acad. Sci. USA 94: 684-689.
- Antisense oligonucleotides utilized in the invention may conveniently be synthesized on a suitable solid support using well known chemical approaches, including H-phosphonate chemistry, phosphoramidite chemistry, or a combination of H-phosphonate chemistry and phosphoramidite chemistry (i.e., H-phosphonate chemistry for some cycles and phosphoramidite chemistry for other cycles) .
- Suitable solid supports include any of the standard. solid supports used for solid phase oligonucleotide synthesis, such as controlled-pore glass (CPG) (see, e.g., Pon, R.T. (1993) Methods in Molec . Biol. 20: 465-496).
- CPG controlled-pore glass
- Particularly preferred oligonucleotides have nucleotide sequences of from about 13 to about 35 nucleotides which include the nucleotide sequences shown in Table 1. Yet additional particularly preferred oligonucleotides have nucleotide sequences of from about 15 to about 26 nucleotides of the nucleotide sequences shown in Table 1.
- Step 1 Methyl-4- [ (4, 6-dichloro- [1,3,5] triazin-2-yl-amino) -methyl] - benzoate (compound 3)
- Step 2 Methyl-4- [ (4-amino-6-chloro- [1,3,5] triazin-2-yl-amino) -methyl] - benzoate (compound 4)
- Step 2 Methyl 4- [ (4-chloro-6 ⁇ (2-indanyl-amino) - [1, 3 , 5] triazin-2-yl- amino) -methyl] -benzoate (compound 5)
- Step 3 Methyl- - [ (4-amino-6- (2-indanyl-amino) -[1,3,5] triazin-2-yl- amino) -methyl] -benzoate (compound 6)
- Step 4 4- [ (4-Amino-6- (2-indanyl-amino) -[1,3,5] triazin-2-yl-amino) - methyl] -benzoic acid (compound 7)
- Step 5 4- ⁇ [4-Amino-6- (2-indanyl-amino) -[1,3, 5]-triazin-2-yl-amino] - methyl ⁇ -N- (2-amino-phenyl) -benzamide (compound 8)
- Examples 2 to 28 describe the preparation of compounds 9 to 35 using the same procedure as described for compound 8 of Example 1. Characterization data are presented in Tables 2a and 2b.
- Step 1 -y-Acetyl-l-piperonylpiperazine (compound 37)
- Step 2 2-Chloro-4-morpholin-4-yl-6- [2- (4-benzo [1, 3] dioxol-5-ylmethyl- piperazin-1-yl) -2-oxo-ethyl] - [1,3,5] riazine (compound 38) [0176] To a stirred solution of 37 (3.00 g, 11.4 mmol) in anhydrous THF (25 mL) at -78°C was slowly added a solution of LiHMDS (11.4 mL, 11.4 mmol, 1 M in THF).
- reaction mixture was stirred 1 h at -78°C and a solution of 2, 4-dichloro-6-morpholin-4-yl- [1 / 3 ,5] triazine (2.69 g, 11.4 mmol) in anhydrous THF (25 mL) was added.
- THF anhydrous solvent
- the reaction mixture was slowly warmed up at room temperature and the reaction was quenched after 16 h with a saturated aqueous solution of NH 4 C1.
- the THF was evaporated and the residue was diluted with AcOEt .
- the organic layer was successively washed with sat. NH 4 C1 and brine, dried over anhydrous MgS0 4 , filtered and concentrated.
- Step 3 N- (2-Amino-phenyl) -4- ( ⁇ 4- [2- (4-benzo [1,3] dioxol-5-ylmethyl- piperazin-1-yl) -2-oxo-ethyl] -6-morpholin-4-yl- [1,3,5] triazin-2- ylamino) -methyl) -benzamide (compound 39)
- Step 1 N- (5-Bromo-pyridin-2-yl) -N' -phenyl-ethane-1, 2-diamine
- Step , 2 N- ( 2 -aminophenyl) -6- (2-phenylamino-ethylaminp) -nicotinamide
- Step 1 N- (5-Bromo-pyridin-2-yl) -4-methoxybenzylamine (compound 43) [0180] A mixture of 2, 6-dibromopyridine 41 (6.03 mmol, 2 equiv.) and para-methoxybenzyl amine (413 mg, 3.01 mmol) was stirred under nitrogen at 120°C for 6h. After identical work-up procedure described before and purification through a pad of silica gel (elution 50% ether in hexanes), a pale yellow solid 43 (773 mg, 2.60 mmol, 87% yield) was obtained.
- Step 2 3- [6- (2-Phenylamino-ethylamino) - pyridin-3-yl) -acrylic acid tert-butyl ester (compound 46)
- Step 4 N- (2-aminophenyl) -3- [6- (2-phenylamino-ethylamino) -pyridin-3- yl] -acrylamide (compound 50)
- Step 2 N- (2 -aminophenyl) -3- [6- (4-methoxy-benzylamino) -pyridin-2-yl] - acrylamide (compound 51)
- Step 1 (4-bromo-benzyl) -carbamic acid pyridin-3 -yl-methyl ester
- Step 2 4- [2- (2-amino-phenylcarbamoyl) -vinyl] -benzyl ⁇ -carbamic acid pyridin-3 -yl methyl ester (compound 55)
- Step 1 (4-Bromo-benzyl) - (3, 4, 5-trimethoxy-benzyl) -amine (compound 57) [0188] To a stirred suspension of K 2 C0 3 (522 mg, 3.77 mmol) in dry DMF was added 3 , 4, 5-trimethoxybenzylamine (1.10 mL, 6.44 mmol, 2.2 equiv.) followed by a solution of p-bromo benzylbromide (0.73 g, 2.91 mmol) in dry DMF (8 mL) .
- Step 2 Jf- (2-Nitro-phenyl) -3- ⁇ 4-[(3,4, 5-trimethoxy-benzylamino) - methyl] -phenyl) -acrylamide (compound 58)
- Step 3 N- (2-aminophenyl) -3 - ⁇ 4- [ (3 ,4, 5-trimethoxy-benzylamino) - methyl] -phenyl) -acrylamide (59)
- Step 1 3- ⁇ 4- ⁇ [Methyl- (3,4, 5-trimethoxy-benzyl) -amino] -methyl) - phenyl) -N- (2-nitro-phenyl) -acrylamide (compound 60)
- Step 2 N- (2-aminophenyl) -3- (4- ⁇ [ (3,4, 5-trimethoxy-benzyl) -amino] - methyl)- phenyl) -acrylamide (compound 61)
- Step 1 Methyl-3- (4-amino-phenyl) -acrylate hydrochloride (compound 63)
- 4-amino-cinnamic acid (10.41 g, 0.052 mol) was dissolved in methanol (100 mL) at rt .
- a solution of HC1 in dioxane (15.6 mL, 4 N) was then added.
- the reaction mixture was heated at reflux overnight.
- the clear solution was evaporated to a half volume and then settled down at rt .
- the white suspension obtained was collected by vacuum filtration.
- the mother liquid was evaporated again to a quart volume and cooled down to rt .
- the suspension was filtered again.
- Step 3 N- (2-aminophenyl) -3- ⁇ 4- (4-methoxy-benzylamino) -phenyl ⁇ - acrylamide (compound 65)
- Step 2 N- (2-Amino-phenyl) -3- (4-styrylamino-phenyl) -acrylamide (71) [0197] Following the procedure described in Example 42, steps 2, 4, but substituting 69 for 42, and acrylic acid for tert-butyl acrylate the title compound 71 was obtained in an overall yield of 60%.
- Step 2 N- (2-Amino-phenyl) -3- [4- (4-methoxy-benzamide) ] -acrylamide
- Step 2 4-Benzyl-l- [2- (5-bromo-pyridin-2-ylamino) -ethyl] -piperazine- 2,6-dione (compound 77)
- Step 3 N- (2-aminophenyl) -3- ⁇ 6- [2- (4-benzyl-2, 6-dioxo-piperazin-l-yl) - ethylamino] -pyridin-3 -yl)-acrylamide (compound 78)
- Step 1 4, 6-Dichloro-2- (2-indanyl-amino) - [1,3,5] triazine (compound 79) [0205]
- cyanuric chloride 13.15 g, 71.33 mmol
- i-Pr 2 NEt 14.39 mL, 82.59 mmol
- anhydrous THF 60 mL
- Step 2 2- (4-Bromo-benzyl-amino) -4-chloro-6- (2-indanyl-amino) - [1, 3 , 5] triazine (compound 80)
- Step 3 4-Amino-2- (4-bromo-benzyl-amino) -6- (2-indanyl-amino) -
- Step 4 (E) -4- ⁇ [4 -Amino -6- (2-indanyl-amino) - [1, ,3,5] triazin-2- -yl- amino] -methyl ⁇ -JV- [2- AN- t-butoxycarbonyl) ⁇ -amino- -phenyl] • -cinamide
- Step 5 (E) -4- ⁇ [4-Amino-6- (2-indanyl-amino) - [1,3 , 5] triazin-2-yl- a ino] -methyl ⁇ -N- (2 -amino-phenyl) -cinnamide (compound 83) [0210] To a stirred solution at room temperature of 82 (230 mg, 0.39 mmol) in CH 2 C1 2 (5 mL) was added TFA (1 mL, 95% in water) . After 18 h, the reaction mixture was poured into a saturated aqueous solution of NaHC0 3 , and diluted with AcOEt. After separation, the organic layer was successively washed with sat.
- Step 1 2, 6-ditrifluoromethanesulfonyloxy-quinoline (compound 85): [0211] A solution of 2, 6-dihydroxyquinoline 84 (1.254 g, 7.78 mmol) and DMAP (a few crystals) in dry pyridine (15 mL) was treated with neat trifluoromethanesulfonic anhydride (5.2 g, 18,4 mmol, 1.2 equiv.) and stirred at 0°C for 5 h. This solution was then poured on a mixture brine/sat NaHC0 3 and extracted with dichloromethane (2 x 150 mL) , dried (MgS0 4 ) , filtered and concentrated.
- Step 2 N- (2-aminophenyl) -2- (4-methoxy-benzylamino) -quinolin-6-yl- amide (compound 87)
- Step 3 N- (2-aminophenyl) -3- [2- (4-methoxy-benzylamino) -quinolin-6-yl] - acrylamide (compound 88)
- Examples 55-84 describe the preparation of compounds 89 to 118 using the same procedures as described for compounds 44 to 88 in Examples 40 to 54. Characterization data are presented in Tables 3a- d.
- Step 1 4- (lH-Benzimidazol-2-ylsulfanylmethyl) -benzoic acid methyl ester (compound 122)
- Step 2 N- (2-Amino-phenyl) -4- (lH-benzimidazol-2-ylsulfanylmethyl) - benzamide (126)
- Step 1 4- (6-Amino-benzothiazol-2-ylsulfanylmethyl) -benzoic acid methyl ester (122)
- Step 2 4- [6- (2-Morpholin-4-yl-ethylamino) -benzothiazol-2- ylsulfanylmethyl] -benzoic acid methyl ester (compound 124) [0218] To a solution of 4- (6-Amino-benzothiazol-2-ylsulfanylmethyl) - benzoic acid methyl ester 122 (800 mg, 2.42 mmol), in DMF (24 mL) , were added successively solid 4- (2-chloroethyl) morpholine hydrochloride (296 mg, 2.66 mmol), K 2 C0 3 (611 mg, 5.08 mmol), Nai (363 mg, 2.42 mmol), Et 3 N (370 ⁇ L, 2.66 mmol) and t
- Step 3 N- (2-Amino-phenyl) -4- [6- (2-morpholin-4-yl-ethylamino) - benzothiazol-2-ylsulfanylmethyl] -benzamide (compound 128) [0219] Following the procedure described in Example 1, steps 4 and 5, but substituting 124 for 6, the title compound 128 was obtained in 76% yield.
- Step 2 N- (2-Amino-phenyl) -4- (quinolin-2-ylsulfanylmethyl) -benzamide (131)
- Step 1 4- (Pyrimidin-2-ylaminomethyl) -benzoic acid methyl ester (compound 133)
- Step 2 N- (2-Amino-phenyl) -4- (pyrimidin-2-ylaminomethyl) -benzamide (134)
- Step 1 [2- (4-Iodo-benzoylamino) -phenyl] -carbamic acid fcert-butyl ester (compound 135)
- Step 2 N- [2- tert-butoxycarbonylamino-phenyl) -terephtalamic acid methyl ester (compound 136)
- Step 4 ⁇ 2- [4- (l-Methyl-imidazol-2-ylsulfanylmethyl) -benzoylamino] ⁇ phenyl ⁇ -carbamic acid tert-butyl ester (compound 138) [0228] To a solution of ir-methyl-2-mercaptoimidazole (28 mg, 0.25 mmol) in THF (1 mL) , at r.t. under N 2 atmosphere were successively added 137 (70 mg, 0.20 mmol), triphenylphosphine (70 mg, 0.27 mmol) followed by dropwise addition of diethyl azodicarboxylate (48 ⁇ L, 0.31 mmol) .
- Step 1 4- (1-Oxo-l, 3-dihydro-isoindol-2-ylmethyl) -benzoic acid
- Step 2 N- (2-Amino-phenyl) -4- (1-oxo-l, 3 -dihydro-isoindol-2-ylmethyl) - benzamide (compound 144)
- Step 1 2- [2- (4-Hydroxy-phenyl) -ethyl] -isoindole-1, 3-dione (compound 150)
- Step 3 N- (2-Amino-phenyl) -4- [2- (1, 3-dioxo-l, 3-dihydro-isoindol-2-yl) - ethyl] -benzamide (compound 152)
- Step 1 4- [ (2-Amino-benzoylamino) -methyl] -benzoic acid (compound 156)
- 4-aminomethylbenzoic acid 5.09 g, 33.7 mmol
- H 2 0 50 mL
- Et 3 N 4.7 mL, 33.7 mmol
- isatoic anhydride 153 5.0 g, 30.6 mmol
- the brown mixture was heated at 40°C for 2 h until the mixture became homogeneous and then Et 3 N was removed in vacuo.
- the resulting aqueous solution was acidified (10%
- Step 2 N- (2-Amino-phenyl) -4- (2, 4-dioxo-l,4-dihydro-2H-quinazolin-3- ylmethyl) -benzamide (compound 157)
- Step 2 -4- ( 1-Methyl-2 , 4-dioxo-1, 4-dihydro-2H-quinazolin-3 -ylmethyl) - benzoic acid methyl ester
- Step 3 4- (l-Methyl-2,4-dioxo-l,4-dihydro-2H-quinazolin-3-ylmethyl) - benzoic acid •
- Step 4 N- (2-Amino-phenyl) -4- (1-methyl-2 , 4-dioxo-l, 4-dihydro-2H- quinazolin-3 -ylmethyl) -benzamide (compound 158)
- Step 3 N- (2 -aminophenyl) -2- (4-Methoxy-benzylamino) -thiazol-5-yl-amide
- Examples 102-121 [0253] Examples 102 to 121 describe the preparation of compounds 164 to 183 using the same procedures as described for compounds 62 to 163 in Examples 47 to 101. Characterization data are presented in Tables 4a and 4b.
- Step 1 ⁇ 2- [ (3' -Formyl-biphenyl-4-carbonyl) -amino] -phenyl ⁇ -carbamic acid tert-butyl ester (185)
- Step 2 N- (2-Aminophenyl) -4- [3- (indan-2 -ylaminomethyl) phenyl) 3 - benzamide (186)
- Examples 123-126 [0257] Examples 123 to 126 (compounds 187 - 190) were prepared using the same procedure as described for compound 186 in Example 122 (scheme 21) .
- Step 1 ⁇ 2- [4- (1-Amino-cyclohexylethynyl) -benzoylamino] -phenyl ⁇ - carbamic acid tert-butyl ester (191)
- Step 2 N- (2 -Aminophenyl) -4- [1- (4-methoxy-benzylamino) - cyclohexylethynyl] -benzamide (192)
- Step 1 N- [2- (t-Butyloxycarbonyl) -amino-phenyl] -4- (trimethylsilylethynyl)benzamide (197)
- Step 2 N- (2-Amino-phenyl) -4- (trimethylsilylethynyl) benzamide (198)
- Step 2 N- (2-amino-phenyl) -4- [3- (4-chlorophenyl) -3-morpholin-4-yl-l- propyn-1-yl] -benzamide (201)
- Step 1 Methyl 4- (4-chloro-6- (2-indanyl-amino) - [1, 3 , 5] triazin-2-yl- amino) -benzoic ester (203)
- Step 2 4- [4-amino-6- (2-indanyl-amino) -[1, 3 , 5]-triazin-2-ylamino] -N- (2-amino-phenyl) -benzamide (204)
- Step 1 Methyl 4- [ (4-chloro-6- (2-indanyl-amino) - [1, 3 , 5] triazin-2- yloxy) -methyl] -benzoic ester (206)
- Step 2 4- ⁇ [4-amino-6- (2-indanyl-amino) -[1,3, 5]-triazin-2-yloxy] - methyl ⁇ -N- (2-amino-phenyl) -benzamide (207) [0268] The title compound 207 was obtained from 206 in 3 steps following the same procedure as Example 1, Pathway B steps 3-5 ⁇
- Step 1 Methyl 4- [ (4, 6-dimethoxy- [1,3, 5] triazin-2-yl-amino) -methyl] - benzoic ester (211)
- Step 2 N- (2-Amino-phenyl) -4- [ (4, 6-dimethoxy-[l/3 , 5]-triazin-2-yl- amino) -methyl] -benzamide (212)
- Step 1 4- [ (6- (2-Indanyl-amino) -4-methoxy- [1,3,5] triazin-2-yl- amino) -methyl] -benzoic acid (213)
- Step 2 N- (2-amino-phenyl) -4- ⁇ [6- (2-indanyl-amino) -4-methoxy-[1, 3 , 5]- triazin-2-yl-amino] -methyl ⁇ -benzamide (214)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA05008246A MXPA05008246A (en) | 2003-02-04 | 2004-02-04 | Inhibitors of histone deacetylase. |
EP04707852A EP1590340B1 (en) | 2003-02-04 | 2004-02-04 | Inhibitors of histone deacetylase |
CA002515338A CA2515338C (en) | 2003-02-04 | 2004-02-04 | Inhibitors of histone deacetylase |
DE602004026407T DE602004026407D1 (en) | 2003-02-04 | 2004-02-04 | Histondeacetylase-hemmer |
AT04707852T ATE463490T1 (en) | 2003-02-04 | 2004-02-04 | HISTONE DEACETYLASE INHIBITORS |
BRPI0407195-6A BRPI0407195A (en) | 2003-02-04 | 2004-02-04 | histone deacetylase inhibitor, composition, and method for inhibiting histone deacetylase in a cell |
AU2004210016A AU2004210016B2 (en) | 2003-02-04 | 2004-02-04 | Inhibitors of histone deacetylase |
JP2005518241A JP3908773B2 (en) | 2003-02-04 | 2004-02-04 | Inhibitors of histone deacetylase |
DK04707852.2T DK1590340T3 (en) | 2003-02-04 | 2004-02-04 | Histone deacetylase inhibitors |
HK06108008.7A HK1087707A1 (en) | 2003-02-04 | 2006-07-18 | Inhibitors of histone deacetylase |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/358,556 US6897220B2 (en) | 2001-09-14 | 2003-02-04 | Inhibitors of histone deacetylase |
US10/358,556 | 2003-02-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004069823A1 true WO2004069823A1 (en) | 2004-08-19 |
Family
ID=32849577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2004/000139 WO2004069823A1 (en) | 2003-02-04 | 2004-02-04 | Inhibitors of histone deacetylase |
Country Status (16)
Country | Link |
---|---|
US (2) | US6897220B2 (en) |
EP (1) | EP1590340B1 (en) |
JP (1) | JP3908773B2 (en) |
KR (1) | KR100893804B1 (en) |
CN (1) | CN100540547C (en) |
AT (1) | ATE463490T1 (en) |
AU (1) | AU2004210016B2 (en) |
BR (1) | BRPI0407195A (en) |
CA (1) | CA2515338C (en) |
DE (1) | DE602004026407D1 (en) |
DK (1) | DK1590340T3 (en) |
ES (1) | ES2341857T3 (en) |
HK (1) | HK1087707A1 (en) |
MX (1) | MXPA05008246A (en) |
PT (1) | PT1590340E (en) |
WO (1) | WO2004069823A1 (en) |
Cited By (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005063239A1 (en) * | 2003-12-23 | 2005-07-14 | Boehringer Ingelheim International Gmbh | 3-(4-piperidine-1ylmethyl-phenyl)-propion acid-phenylamide-derivatives and related compounds used in the form of mch antagonists (melanine concentrating hormone) for treating eating disorders |
WO2006069096A1 (en) * | 2004-12-20 | 2006-06-29 | Pharmacyclics, Inc. | Silanol derivatives as inhibitors of histone deacetylase |
JP2007001885A (en) * | 2005-06-21 | 2007-01-11 | Univ Kansai | Carboxamide derivative |
WO2007055941A2 (en) | 2005-11-03 | 2007-05-18 | Merck & Co., Inc. | Histone deacetylase inhibitors with aryl-pyrazolyl motifs |
US7253204B2 (en) | 2004-03-26 | 2007-08-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
JP2007530459A (en) * | 2004-03-26 | 2007-11-01 | メシルジーン、インコーポレイテッド | Inhibitors of histone deacetylase |
US7351719B2 (en) | 2002-10-31 | 2008-04-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds |
WO2008041053A2 (en) | 2005-05-20 | 2008-04-10 | Methylgene, Inc. | Inhibitors of vegf receptor and hgf receptor signaling |
WO2008055068A2 (en) | 2006-10-28 | 2008-05-08 | Methylgene Inc. | Inhibitors of histone deacetylase |
WO2008089436A2 (en) * | 2007-01-18 | 2008-07-24 | Takeda San Diego, Inc. | Crystalline forms of histone deacetylase inhibitors |
EP1973405A2 (en) * | 2006-01-12 | 2008-10-01 | Merck & Co., Inc. | Hydroxyalkylarylamide derivatives |
WO2008123395A1 (en) | 2007-03-28 | 2008-10-16 | Santen Pharmaceutical Co., Ltd. | Ocular hypotensive agent comprising compound capable of inhibiting histone deacetylase as active ingredient |
US7544695B2 (en) | 2005-11-23 | 2009-06-09 | Merck & Co., Inc. | Spirocyclic compounds |
US7589197B2 (en) | 2005-06-14 | 2009-09-15 | Taigen Biotechnology | Pyrimidine compounds |
US7592373B2 (en) | 2003-12-23 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds |
US7595343B2 (en) | 2001-09-14 | 2009-09-29 | Methylgene, Inc. | Inhibitors of histone deacetylase |
US7732475B2 (en) | 2005-07-14 | 2010-06-08 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US7772238B2 (en) | 2005-04-20 | 2010-08-10 | Merck Sharp & Dohme Corp. | Benzothiophene hydroxamic acid derivatives |
WO2010110545A2 (en) | 2009-03-27 | 2010-09-30 | 주식회사종근당 | Novel hydroxamate derivative, a production method for the same, and a pharmaceutical composition comprising the same |
US7834034B2 (en) | 2005-04-20 | 2010-11-16 | Merck Sharp & Dohme Corp. | Benzothiophene derivatives |
US7838520B2 (en) | 2001-09-14 | 2010-11-23 | Methylgene, Inc. | Inhibitors of histone deacetylase |
US7868205B2 (en) | 2003-09-24 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
US7868204B2 (en) | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
US7872024B2 (en) | 2005-04-20 | 2011-01-18 | Merck Sharp & Dohme Corp. | Benzothiophene hydroxamic acid derivatives with carbamate, urea, amide and sulfonamide substitutions |
US7935724B2 (en) * | 2003-10-09 | 2011-05-03 | Merck Hdac Research, Llc | Thiophene and benzothiophene hydroxamic acid derivatives |
US7981874B2 (en) | 2006-07-20 | 2011-07-19 | Merck Sharp & Dohme Corp. | Phosphorus derivatives as histone deacetylase inhibitors |
US8030344B2 (en) | 2007-03-13 | 2011-10-04 | Methylgene Inc. | Inhibitors of histone deacetylase |
US8071615B2 (en) | 2002-03-13 | 2011-12-06 | Janssen Pharmaceutica N.V. | Carbonylamino-derivatives as novel inhibitors of histone deacetylase |
US8101616B2 (en) | 2006-01-19 | 2012-01-24 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
US8114876B2 (en) | 2006-01-19 | 2012-02-14 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
US8114999B2 (en) | 2002-03-13 | 2012-02-14 | Janssen Pharmaceutica N.V. | Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
US8119685B2 (en) | 2006-04-26 | 2012-02-21 | Merck Sharp & Dohme Corp. | Disubstituted aniline compounds |
US8119650B2 (en) | 2006-01-19 | 2012-02-21 | Janssen Pharmaceutica N.V. | Aminophenyl derivatives as novel inhibitors of histone deacetylase |
US8119652B2 (en) | 2006-05-18 | 2012-02-21 | Merck Sharp & Dohme Corp. | Aryl-fused spirocyclic compounds |
US8138198B2 (en) | 2005-05-18 | 2012-03-20 | Angibaud Patrick Rene | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase |
US8158825B2 (en) | 2005-06-24 | 2012-04-17 | Merck Sharp & Dohme Corp. | Modified malonate derivatives |
US8163765B2 (en) | 2006-01-19 | 2012-04-24 | Janssen Pharmaceutica N.V. | Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase |
US8163733B2 (en) | 2002-03-13 | 2012-04-24 | Janssen Pharmaceutica N.V. | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase |
US8168658B2 (en) | 2006-02-28 | 2012-05-01 | Merck Sharp & Dohme Corp. | Inhibitors of histone deacetylase |
US8193205B2 (en) | 2004-07-28 | 2012-06-05 | Janssen Pharmaceutica N.V. | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
US8217079B2 (en) | 2010-03-26 | 2012-07-10 | Italfarmaco Spa | Method for treating Philadelphia-negative myeloproliferative syndromes |
WO2012118632A1 (en) | 2011-02-28 | 2012-09-07 | Ning Xi | Substituted quinoline compounds and methods of use |
EP2532657A2 (en) | 2008-10-14 | 2012-12-12 | Sunshine Lake Pharma Co., Ltd | Compounds and methods of use |
US8372849B2 (en) | 2008-04-21 | 2013-02-12 | Taigen Biotechnology Co., Ltd. | Heterocyclic compounds |
US8389553B2 (en) | 2007-06-27 | 2013-03-05 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
US8461189B2 (en) | 2007-06-27 | 2013-06-11 | Merck Sharp & Dohme Corp. | Pyridyl derivatives as histone deacetylase inhibitors |
US8501737B2 (en) | 2002-03-13 | 2013-08-06 | Janssen Pharmaceutica N.V. | Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase |
US8598168B2 (en) | 2006-04-07 | 2013-12-03 | Methylgene Inc. | Inhibitors of histone deacetylase |
US8642809B2 (en) | 2007-09-25 | 2014-02-04 | Topotarget Uk Ltd. | Methods of synthesis of certain hydroxamic acid compounds |
WO2014022116A2 (en) | 2012-07-28 | 2014-02-06 | Calitor Sciences, Llc | Substituted pyrazolone compounds and methods of use |
WO2014130375A1 (en) | 2013-02-21 | 2014-08-28 | Calitor Sciences, Llc | Heteroaromatic compounds as pi3 kinase modulators |
US8828392B2 (en) | 2005-11-10 | 2014-09-09 | Topotarget Uk Limited | Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent |
US8835501B2 (en) | 2005-05-13 | 2014-09-16 | Topotarget Uk Limited | Pharmaceutical formulations of HDAC inhibitors |
WO2014178606A1 (en) | 2013-04-29 | 2014-11-06 | Chong Kun Dang Pharmaceutical Corp. | Novel compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same |
US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
US9023834B2 (en) | 2008-11-13 | 2015-05-05 | Taigen Biotechnology Co., Ltd. | Lyophilization formulation |
KR101528617B1 (en) * | 2011-10-28 | 2015-06-19 | 주식회사 종근당 | Hydroxamate Derivatives for HDAC Inhibitor, and the pharmaceutical composition comprising thereof |
KR20150068923A (en) | 2013-12-12 | 2015-06-22 | 주식회사 종근당 | Aza-indole Derivatives for HDAC Inhibitor, and the pharmaceutical composition comprising thereof |
KR20150081132A (en) | 2014-01-03 | 2015-07-13 | 주식회사 종근당 | Indole Derivatives Compound, and the pharmaceutical composition comprising the same |
US9265734B2 (en) | 2008-09-03 | 2016-02-23 | Biomarin Pharmaceutical Inc. | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors |
WO2016190630A1 (en) | 2015-05-22 | 2016-12-01 | Chong Kun Dang Pharmaceutical Corp. | Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same |
US9540395B2 (en) | 2011-02-28 | 2017-01-10 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
WO2017067447A1 (en) | 2015-10-19 | 2017-04-27 | Sunshine Lake Pharma Co., Ltd. | A salt of egfr inhibitor, crystalline form and uses thereof |
US9636298B2 (en) | 2014-01-17 | 2017-05-02 | Methylgene Inc. | Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs |
EP3299019A1 (en) | 2012-11-14 | 2018-03-28 | Calitor Sciences, LLC | Heteroaromatic compounds as pi3 kinase modulators and methods of use |
WO2018054960A1 (en) | 2016-09-21 | 2018-03-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting and treating resistance to chemotherapy in npm-alk(+) alcl |
US10029988B2 (en) | 2013-03-15 | 2018-07-24 | Biomarin Pharmaceutical Inc. | HDAC inhibitors |
US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
US10285959B2 (en) | 2005-02-03 | 2019-05-14 | Topotarget Uk Limited | Combination therapies using HDAC inhibitors |
US10688047B2 (en) | 2015-11-03 | 2020-06-23 | Italfarmaco Spa | Physically and chemically stable oral suspensions of givinostat |
EP3769757A3 (en) * | 2013-10-18 | 2021-10-06 | The General Hospital Corporation | Imaging histone deacetylases with a radiotracer using positron emission tomography |
US11938134B2 (en) | 2017-03-10 | 2024-03-26 | Eikonizo Therapeutics, Inc. | Metalloenzyme inhibitor compounds |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
KR20020070285A (en) | 1999-11-23 | 2002-09-05 | 메틸진, 인크. | Inhibitors of histone deacetylase |
US20030129724A1 (en) * | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
US7244853B2 (en) | 2001-05-09 | 2007-07-17 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
US20050176686A1 (en) * | 2002-07-23 | 2005-08-11 | 4Sc Ag | Novel compounds as histone deacetylase inhibitors |
AR044743A1 (en) * | 2002-09-26 | 2005-10-05 | Nihon Nohyaku Co Ltd | HERBICIDE, METHOD OF USE, DERIVED FROM REPLACED TIENOPIRIMIDINE, INTERMEDIATE COMPOUNDS, AND PROCEDURES USED TO PRODUCE THEM, |
US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US7250514B1 (en) | 2002-10-21 | 2007-07-31 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
WO2004082638A2 (en) | 2003-03-17 | 2004-09-30 | Syrrx, Inc. | Histone deacetylase inhibitors |
EP1680109A4 (en) * | 2003-10-07 | 2009-05-06 | Renovis Inc | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
CN1989131A (en) * | 2004-03-30 | 2007-06-27 | 希龙公司 | Substituted thiophene derivatives as anti-cancer agents |
EP1824831A2 (en) | 2004-12-16 | 2007-08-29 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US7576099B2 (en) * | 2005-02-28 | 2009-08-18 | Renovis, Inc. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
BRPI0606365A2 (en) * | 2005-02-28 | 2017-06-27 | Renovis Inc | compound or a pharmaceutically acceptable salt, solvate or prodrug thereof and stereoisomers and tautomers thereof, pharmaceutical composition, methods for preventing, treating, ameliorating or controlling a disease or condition and for preparing a compound, use of a compound or a salt , solvate or pharmaceutically acceptable composition thereof, method of treating a mammal, and, combination |
AU2006226861B2 (en) | 2005-03-22 | 2012-08-16 | Dana-Farber Cancer Institute, Inc. | Treatment of protein degradation disorders |
JP2008540574A (en) | 2005-05-11 | 2008-11-20 | タケダ サン ディエゴ インコーポレイテッド | Histone deacetylase inhibitor |
EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
JP2009506069A (en) | 2005-08-26 | 2009-02-12 | ブレインセルス,インコーポレイティド | Neurogenesis through modulation of muscarinic receptors |
JP2009512711A (en) | 2005-10-21 | 2009-03-26 | ブレインセルス,インコーポレイティド | Regulation of neurogenesis by PDE inhibition |
AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
JP2009514859A (en) * | 2005-11-03 | 2009-04-09 | メルク エンド カムパニー インコーポレーテッド | Substituted nicotinamide compounds |
CA2635209A1 (en) * | 2006-01-12 | 2007-08-02 | Merck & Co., Inc. | Fluorinated arylamide derivatives |
EP1976835A2 (en) * | 2006-01-13 | 2008-10-08 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
ATE539073T1 (en) | 2006-01-19 | 2012-01-15 | Janssen Pharmaceutica Nv | HETEROCYCLYLALKYL DERIVATIVES AS NEW INHIBITORS OF HISTONE DEACETYLASE |
ES2402213T3 (en) | 2006-01-19 | 2013-04-29 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as histone deacetylase inhibitors |
JP5441416B2 (en) | 2006-02-14 | 2014-03-12 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | Bifunctional histone deacetylase inhibitor |
ES2481413T3 (en) | 2006-02-14 | 2014-07-30 | The President And Fellows Of Harvard College | Histone Deacetylase Inhibitors |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
WO2007107005A1 (en) * | 2006-03-22 | 2007-09-27 | Methylgene, Inc. | Inhibitors of protein tyrosine kinase activity |
EP2019674B1 (en) * | 2006-05-03 | 2016-11-23 | The President and Fellows of Harvard College | Histone deacetylase and tubulin deacetylase inhibitors |
US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
WO2008035209A2 (en) * | 2006-05-30 | 2008-03-27 | Methylgene Inc. | Inhibitors of protein tyrosine kinase activity |
US8633175B2 (en) * | 2006-08-09 | 2014-01-21 | Glaxosmithkline Llc | Compounds as antagonists or inverse agonists at opioid receptors |
US7998971B2 (en) | 2006-09-08 | 2011-08-16 | Braincells Inc. | Combinations containing a 4-acylaminopyridine derivative |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
EP1939180A1 (en) * | 2006-12-20 | 2008-07-02 | sanofi-aventis | Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase |
JP5150332B2 (en) * | 2007-03-28 | 2013-02-20 | 参天製薬株式会社 | Novel pyridinecarboxylic acid (2-aminophenyl) amide derivatives having a urea structure |
JP2010539104A (en) * | 2007-09-14 | 2010-12-16 | メチルジーン インコーポレイテッド | Combination therapy of cancer with selective inhibitors of histone deacetylases HDAC1, HDAC2 and / or HDAC3 and microtubule stabilizers |
CN101808999B (en) * | 2007-09-27 | 2013-02-13 | 弗·哈夫曼-拉罗切有限公司 | Quinoline derivatives as 5HT5A receptor antagonists |
JP2011501746A (en) * | 2007-10-10 | 2011-01-13 | オーキッド リサーチ ラボラトリーズ リミテッド | Novel histone deacetylase inhibitor |
US20090156825A1 (en) * | 2007-11-26 | 2009-06-18 | Heidebrecht Jr Richard W | Fluorescent compounds that bind to histone deacetylase |
CA2706750A1 (en) * | 2007-11-27 | 2009-06-04 | Ottawa Health Research Institute | Amplification of cancer-specific oncolytic viral infection by histone deacetylase inhibitors |
WO2009089598A2 (en) * | 2008-01-18 | 2009-07-23 | Katholieke Universiteit Leuven | Msmb-gene methylation based diagnosis, staging and prognosis of prostate cancer |
SI2262493T1 (en) * | 2008-03-07 | 2015-07-31 | Onxeo Dk Branch Of Onxeo S.A. France | Methods of treatment employing prolonged continuous infusion of belinostat |
CA2726164A1 (en) * | 2008-05-27 | 2009-12-23 | The Board Of Regents Of The University Of Texas System | Wnt protein signalling inhibitors |
WO2010011700A2 (en) | 2008-07-23 | 2010-01-28 | The Brigham And Women's Hospital, Inc. | Treatment of cancers characterized by chromosomal rearrangement of the nut gene |
CA2731730C (en) * | 2008-07-23 | 2017-06-13 | President And Fellows Of Harvard College | Deacetylase inhibitors and uses thereof |
GB0900555D0 (en) * | 2009-01-14 | 2009-02-11 | Topotarget As | New methods |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
US8716344B2 (en) | 2009-08-11 | 2014-05-06 | President And Fellows Of Harvard College | Class- and isoform-specific HDAC inhibitors and uses thereof |
CN102020607B (en) * | 2009-09-16 | 2013-01-23 | 深圳微芯生物科技有限责任公司 | 6-aminoniacinamide derivatives with histone deacetylase inhibiting activity, preparation method and application thereof |
JP2013508458A (en) | 2009-10-26 | 2013-03-07 | ラモット・アット・テル−アヴィヴ・ユニヴァーシティ・リミテッド | Cancer treatment using a combination of FTS and HDAC inhibitor |
JP5607241B2 (en) | 2010-05-21 | 2014-10-15 | ケミリア・エービー | New pyrimidine derivatives |
WO2012054332A1 (en) * | 2010-10-18 | 2012-04-26 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
WO2012068589A2 (en) * | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
BR112013024378A2 (en) | 2011-03-24 | 2016-12-13 | Chemilia Ab | new pyrimidine derivatives |
EA201490228A1 (en) | 2011-07-08 | 2014-08-29 | Новартис Аг | NEW DERIVATIVES OF TRIFTOROMETHYLOROXIAZOLE AND THEIR APPLICATION FOR THE TREATMENT OF DISEASE |
EP2780013A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | Modulators of methyl modifying enzymes, compositions and uses thereof |
EP2780014A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | Modulators of methyl modifying enzymes, compositions and uses thereof |
EA201491060A1 (en) * | 2011-11-28 | 2014-09-30 | Новартис Аг | NEW DERIVATIVES OF TRIFTOROMETHYLOROXIAZOLE AND THEIR APPLICATION FOR THE TREATMENT OF DISEASE |
WO2013090369A1 (en) * | 2011-12-12 | 2013-06-20 | Smb Innovation | Novel heterocyclic compounds useful in sirtuin binding and modulation |
WO2013120104A2 (en) | 2012-02-10 | 2013-08-15 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
US9499496B2 (en) | 2012-06-05 | 2016-11-22 | University Of Kansas | Inhibitors of respiratory syncytial virus |
US9000016B2 (en) * | 2012-11-05 | 2015-04-07 | Allergan, Inc. | 1,3,4-Oxadiazoles-2-thio derivatives as sphingosine-1 phosphate receptors modulators |
US9096549B2 (en) | 2013-02-01 | 2015-08-04 | Acetylon Pharmaceuticals, Inc. | Selective HDAC3 inhibitors |
US9139583B2 (en) | 2013-02-01 | 2015-09-22 | Acetylon Pharmaceuticals, Inc. | Selective HDAC3 inhibitors |
EP2970305B1 (en) | 2013-03-15 | 2017-02-22 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
WO2015005491A1 (en) * | 2013-07-12 | 2015-01-15 | 国立大学法人京都大学 | Method for screening substance capable of inhibiting abnormal splicing causative of onset or progress of disease |
WO2015006875A1 (en) * | 2013-07-18 | 2015-01-22 | Methylgene Inc. | Process for the preparation of substituted pyrimidines |
EP3033334A1 (en) | 2013-08-15 | 2016-06-22 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
JO3554B1 (en) | 2013-10-14 | 2020-07-05 | Eisai R&D Man Co Ltd | Selectively Substituted Quinoline Compounds |
WO2015057655A1 (en) | 2013-10-14 | 2015-04-23 | Eisai R&D Management Co., Ltd. | Selectively substituted quinoline compounds |
MY197262A (en) | 2015-07-27 | 2023-06-08 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
KR101799009B1 (en) | 2015-07-27 | 2017-11-17 | 주식회사 종근당 | 1,3,4-Oxadiazole Amide Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same |
JP6538266B2 (en) | 2015-07-27 | 2019-07-03 | チョン クン ダン ファーマシューティカル コーポレーション | 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions containing the same (1, 3, 4-Oxadiazole Sulfamide Derivatives Compounds as Histone Deacetylase 6 Inhibitor , And the Pharmaceutical Composition Composing the same) |
BR112018002304B1 (en) | 2015-08-04 | 2023-12-19 | Chong Kun Dang Pharmaceutical Corp | COMPOUNDS OF 1,3,4-OXADIAZOLE DERIVATIVE AS A HISTONE DEACETYLASE 6 INHIBITOR AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME |
WO2017040190A1 (en) | 2015-08-28 | 2017-03-09 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide |
NZ740809A (en) | 2015-10-12 | 2019-04-26 | Chong Kun Dang Pharmaceutical Corp | Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
TWI794171B (en) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-l1 inhibitors |
TWI808055B (en) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-1 inhibitors |
CN109843870A (en) | 2016-10-19 | 2019-06-04 | 星座制药公司 | The synthesis of EZH2 inhibitor |
KR102034490B1 (en) * | 2016-12-27 | 2019-10-21 | 미츠비시 히타치 쓰루 가부시키가이샤 | Cutting inserts and blade tip interchangeable rotary cutting tools |
KR101964810B1 (en) * | 2017-10-12 | 2019-04-02 | 충북대학교 산학협력단 | Novel N-Hydroxybenzamides or N-Hydroxypropenamides Incorporating Quinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Anticancer Composition Comprising the Same |
KR102316234B1 (en) | 2018-07-26 | 2021-10-22 | 주식회사 종근당 | 1,3,4-Oxadiazole Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0847992A1 (en) * | 1996-09-30 | 1998-06-17 | Mitsui Chemicals, Inc. | Benzamide derivatives, useful as cell differentiation inducers |
WO2001038322A1 (en) * | 1999-11-23 | 2001-05-31 | Methylgene, Inc. | Inhibitors of histone deacetylase |
WO2003024448A2 (en) * | 2001-09-14 | 2003-03-27 | Methylgene, Inc. | Inhibitors of histone deacetylase |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2754286A (en) * | 1951-10-15 | 1956-07-10 | Du Pont | Aldehydes and their acetals |
CH431764A (en) * | 1959-05-06 | 1967-03-15 | Sandoz Ag | Process for the production of metal-containing reactive dyes |
IL22272A (en) | 1963-11-06 | 1969-02-27 | Merck & Co Inc | 2-heteroaryl-5(or 6)-aryl substituted benzazoles |
CH477163A (en) * | 1967-07-26 | 1969-10-15 | Ciba Geigy | Use of salicylic acid-o-hydroxyphenylamides for antimicrobial finishing or for protecting textile material against harmful microorganisms |
US4994479A (en) * | 1985-04-03 | 1991-02-19 | Yamanouchi Pharmaceutical Co., Ltd. | Phenylene derivatives and anti-allergic use thereof |
NZ219974A (en) * | 1986-04-22 | 1989-08-29 | Goedecke Ag | N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases |
US5149797A (en) * | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
US5332750A (en) * | 1991-09-04 | 1994-07-26 | Merck Patent Gesellschaft Mit Beschrankter Haftung | 1,2-dihydro-2-oxopyridines |
US5652355A (en) * | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
DE4339868A1 (en) | 1993-11-23 | 1995-05-24 | Merck Patent Gmbh | imidazopyridazines |
JP3668494B2 (en) * | 1994-05-31 | 2005-07-06 | 帝人株式会社 | Naphthalene derivatives |
DE19510957A1 (en) | 1995-03-25 | 1996-09-26 | Huels Chemische Werke Ag | Thickened soil stabilizer, as well as packaged ready mix for soil treatments containing it |
US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
JP4105451B2 (en) | 1996-09-30 | 2008-06-25 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | Differentiation inducer |
US6794392B1 (en) * | 1996-09-30 | 2004-09-21 | Schering Aktiengesellschaft | Cell differentiation inducer |
AU6422098A (en) | 1997-03-24 | 1998-10-20 | Kyowa Hakko Kogyo Co. Ltd. | Benzene derivatives |
FR2761986B1 (en) | 1997-04-09 | 1999-05-21 | Hoechst Schering Agrevo Sa | NOVEL AROMATIC AMIDES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS PESTICIDES |
US6034251A (en) * | 1997-11-07 | 2000-03-07 | Schering Corporation | Phenyl-alkyl-imidazoles |
JPH11318492A (en) * | 1998-03-09 | 1999-11-24 | Aisin Seiki Co Ltd | Composition containing fluorogenic substrate |
JPH11269146A (en) | 1998-03-24 | 1999-10-05 | Mitsui Chem Inc | Differentiation-inducting agent |
JP4405602B2 (en) | 1998-04-16 | 2010-01-27 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | Histone deacetylase inhibitor |
WO2000003704A1 (en) | 1998-07-20 | 2000-01-27 | Smithkline Beecham Corporation | Macrophage scavenger receptor antagonists |
JP2000256194A (en) | 1999-01-06 | 2000-09-19 | Mitsui Chemicals Inc | Intranuclear receptor agonist and agent for enhancing its effect |
US6653309B1 (en) * | 1999-04-26 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme technical field of the invention |
EP1173562A2 (en) | 1999-05-03 | 2002-01-23 | Methylgene, Inc. | Inhibition of histone deacetylase |
JP2001081031A (en) | 1999-08-30 | 2001-03-27 | Schering Ag | Benzamide derivative-containing preparation having improved solubility and oral adsorption |
US6632815B2 (en) * | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
JP4360660B2 (en) | 1999-11-09 | 2009-11-11 | 三井化学株式会社 | Purification method of monoacylphenylenediamine derivatives |
CA2400264A1 (en) | 2000-02-15 | 2001-08-23 | Teijin Limited | Cancer remedy comprising anthranilic acid derivative as active ingredient |
CA2401778C (en) * | 2000-02-29 | 2010-12-21 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
WO2001068585A1 (en) | 2000-03-14 | 2001-09-20 | Fujisawa Pharmaceutical Co., Ltd. | Novel amide compounds |
EP2093292A2 (en) * | 2000-03-24 | 2009-08-26 | Methylgene, Inc. | Inhibition of specific histone deacetylase isoforms |
JP2003528074A (en) | 2000-03-24 | 2003-09-24 | メチルジーン インコーポレイテッド | Histone deacetylase inhibitor |
KR20040018328A (en) | 2001-01-12 | 2004-03-03 | 메틸진, 인크. | Methods for specifically inhibiting histone deacetylase-4 |
US7067539B2 (en) | 2001-02-08 | 2006-06-27 | Schering Corporation | Cannabinoid receptor ligands |
US7507767B2 (en) * | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
US7868204B2 (en) * | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
JP2003137866A (en) | 2001-11-01 | 2003-05-14 | Sankyo Co Ltd | Phenylenediamine derivative |
IL161439A0 (en) * | 2001-11-14 | 2004-09-27 | Schering Corp | Cannabinoid receptor ligands |
JP4169986B2 (en) | 2001-11-26 | 2008-10-22 | 日本曹達株式会社 | Phenolic compound and recording material using the same |
OA12789A (en) | 2002-03-13 | 2006-07-10 | Janssen Pharmaceutica Nv | Carbonylamino-derivatives as novel inhibitors of histone deacetylase. |
EP1485099B1 (en) | 2002-03-13 | 2010-07-07 | Janssen Pharmaceutica N.V. | Inhibitors of histone deacetylase |
NZ534830A (en) | 2002-03-13 | 2005-08-26 | Janssen Pharmaceutica Nv | Compounds with histone deacetylase HDAC inhibiting activity and oral bioavailability useful for treating proliferative diseases |
US7592450B2 (en) | 2002-03-13 | 2009-09-22 | Janssen Pharmaceutica N.V. | Piperazinyl-, piperidinyl- and morpholinyl-derivatives as inhibitors of histone deacetylase |
PL214279B1 (en) | 2002-03-13 | 2013-07-31 | Janssen Pharmaceutica Nv | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase |
AU2003221366B2 (en) * | 2002-03-14 | 2006-08-31 | Nippon Soda Co., Ltd. | Phenolic compound and recording material containing the same |
TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
GB0209715D0 (en) | 2002-04-27 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
US7217732B2 (en) * | 2002-06-19 | 2007-05-15 | Schering Corporation | Cannabinoid receptor agonists |
US20040072770A1 (en) | 2002-07-03 | 2004-04-15 | Besterman Jeffrey M. | Methods for specifically inhibiting histone deacetylase-7 and 8 |
CA2501265A1 (en) | 2002-10-17 | 2004-04-29 | Methylgene Inc. | Inhibitors of histone deacetylase |
EP1565431B1 (en) * | 2002-11-25 | 2009-06-17 | Schering Corporation | Cannabinoid receptor ligands |
WO2004058234A2 (en) | 2002-12-27 | 2004-07-15 | Schering Aktiengesellschaft | Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors |
US7208491B2 (en) | 2003-02-07 | 2007-04-24 | Hoffmann-La Roche Inc. | N-monoacylated o-phenylenediamines |
US7244751B2 (en) | 2003-02-14 | 2007-07-17 | Shenzhen Chipscreen Biosciences Ltd. | Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity |
TW200505902A (en) * | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
EP1663953A1 (en) | 2003-09-24 | 2006-06-07 | Methylgene, Inc. | Inhibitors of histone deacetylase |
KR101258504B1 (en) | 2004-03-26 | 2013-04-26 | 메틸진 인코포레이티드 | Inhibitors of histone deacetylase |
US7253204B2 (en) * | 2004-03-26 | 2007-08-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
WO2007135471A1 (en) * | 2004-09-22 | 2007-11-29 | Methylgene, Inc. | Histone deacetylase whole cell enzyme assay |
JP2008540574A (en) | 2005-05-11 | 2008-11-20 | タケダ サン ディエゴ インコーポレイテッド | Histone deacetylase inhibitor |
CA2615105A1 (en) | 2005-07-14 | 2007-01-25 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
EP2007720B1 (en) | 2006-04-07 | 2013-12-25 | MethylGene Inc. | Benzamide derivatives as inhibitors of histone deacetylase |
-
2003
- 2003-02-04 US US10/358,556 patent/US6897220B2/en not_active Expired - Lifetime
-
2004
- 2004-02-04 BR BRPI0407195-6A patent/BRPI0407195A/en not_active IP Right Cessation
- 2004-02-04 EP EP04707852A patent/EP1590340B1/en not_active Expired - Lifetime
- 2004-02-04 CA CA002515338A patent/CA2515338C/en not_active Expired - Fee Related
- 2004-02-04 ES ES04707852T patent/ES2341857T3/en not_active Expired - Lifetime
- 2004-02-04 DE DE602004026407T patent/DE602004026407D1/en not_active Expired - Lifetime
- 2004-02-04 MX MXPA05008246A patent/MXPA05008246A/en active IP Right Grant
- 2004-02-04 WO PCT/CA2004/000139 patent/WO2004069823A1/en active Application Filing
- 2004-02-04 PT PT04707852T patent/PT1590340E/en unknown
- 2004-02-04 JP JP2005518241A patent/JP3908773B2/en not_active Expired - Lifetime
- 2004-02-04 AT AT04707852T patent/ATE463490T1/en active
- 2004-02-04 AU AU2004210016A patent/AU2004210016B2/en not_active Ceased
- 2004-02-04 DK DK04707852.2T patent/DK1590340T3/en active
- 2004-02-04 KR KR1020057009963A patent/KR100893804B1/en active IP Right Grant
- 2004-02-04 CN CNB200480001769XA patent/CN100540547C/en not_active Expired - Fee Related
-
2005
- 2005-03-15 US US11/081,095 patent/US7838520B2/en not_active Expired - Lifetime
-
2006
- 2006-07-18 HK HK06108008.7A patent/HK1087707A1/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0847992A1 (en) * | 1996-09-30 | 1998-06-17 | Mitsui Chemicals, Inc. | Benzamide derivatives, useful as cell differentiation inducers |
WO2001038322A1 (en) * | 1999-11-23 | 2001-05-31 | Methylgene, Inc. | Inhibitors of histone deacetylase |
WO2003024448A2 (en) * | 2001-09-14 | 2003-03-27 | Methylgene, Inc. | Inhibitors of histone deacetylase |
Cited By (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7595343B2 (en) | 2001-09-14 | 2009-09-29 | Methylgene, Inc. | Inhibitors of histone deacetylase |
US7868204B2 (en) | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
US7838520B2 (en) | 2001-09-14 | 2010-11-23 | Methylgene, Inc. | Inhibitors of histone deacetylase |
US9150560B2 (en) | 2002-03-13 | 2015-10-06 | Janssen Pharmaceutica Nv | Inhibitors of histone deacetylase |
US8268833B2 (en) | 2002-03-13 | 2012-09-18 | Janssen Pharmaceutica, N.V. | Inhibitors of histone deacetylase |
US9556161B2 (en) | 2002-03-13 | 2017-01-31 | Janssen Pharmaceutica Nv | Inhibitors of histone deacetylase |
US8071615B2 (en) | 2002-03-13 | 2011-12-06 | Janssen Pharmaceutica N.V. | Carbonylamino-derivatives as novel inhibitors of histone deacetylase |
US8114999B2 (en) | 2002-03-13 | 2012-02-14 | Janssen Pharmaceutica N.V. | Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
US8163733B2 (en) | 2002-03-13 | 2012-04-24 | Janssen Pharmaceutica N.V. | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase |
US8524711B2 (en) | 2002-03-13 | 2013-09-03 | Janssen Pharmaceutica N.V. | Amino-derivatives as novel inhibitors of histone deacetylase |
US8501737B2 (en) | 2002-03-13 | 2013-08-06 | Janssen Pharmaceutica N.V. | Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase |
US8455498B2 (en) | 2002-03-13 | 2013-06-04 | Janssen Pharmaceutica N.V. | Inhibitors of histone deacetylase |
US8916554B2 (en) | 2002-03-13 | 2014-12-23 | Janssen Pharmaceutica, N.V. | Amino-derivatives as novel inhibitors of histone deacetylase |
US8343988B2 (en) | 2002-03-13 | 2013-01-01 | Janssen Pharmaceutica, N.V | Inhibitors of histone deacetylase |
US9533979B2 (en) | 2002-03-13 | 2017-01-03 | Janssen Pharmaceutica Nv | Amino-derivatives as novel inhibitors of histone deacetylase |
US7351719B2 (en) | 2002-10-31 | 2008-04-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds |
US7868205B2 (en) | 2003-09-24 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
US7935724B2 (en) * | 2003-10-09 | 2011-05-03 | Merck Hdac Research, Llc | Thiophene and benzothiophene hydroxamic acid derivatives |
WO2005063239A1 (en) * | 2003-12-23 | 2005-07-14 | Boehringer Ingelheim International Gmbh | 3-(4-piperidine-1ylmethyl-phenyl)-propion acid-phenylamide-derivatives and related compounds used in the form of mch antagonists (melanine concentrating hormone) for treating eating disorders |
US7592373B2 (en) | 2003-12-23 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds |
US7253204B2 (en) | 2004-03-26 | 2007-08-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
AU2005225471B2 (en) * | 2004-03-26 | 2011-05-12 | Methylgene Inc. | Inhibitors of histone deacetylase |
JP2007530459A (en) * | 2004-03-26 | 2007-11-01 | メシルジーン、インコーポレイテッド | Inhibitors of histone deacetylase |
US8088805B2 (en) | 2004-03-26 | 2012-01-03 | Methylgene Inc. | Inhibitors of histone deacetylase |
US9150543B2 (en) | 2004-07-28 | 2015-10-06 | Janssen Pharmaceutica N. V. | Substituted indolyl alkyl amino derivatives as inhibitors of histone deacetylase |
US8592441B2 (en) | 2004-07-28 | 2013-11-26 | Janssen Pharmaceutica N.V. | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
US9636341B2 (en) | 2004-07-28 | 2017-05-02 | Janssen Pharmaceutica N.V. | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
US8193205B2 (en) | 2004-07-28 | 2012-06-05 | Janssen Pharmaceutica N.V. | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
WO2006069096A1 (en) * | 2004-12-20 | 2006-06-29 | Pharmacyclics, Inc. | Silanol derivatives as inhibitors of histone deacetylase |
US10799469B2 (en) | 2005-02-03 | 2020-10-13 | Topotarget Uk Limited | Combination therapies using HDAC inhibitors |
US10285959B2 (en) | 2005-02-03 | 2019-05-14 | Topotarget Uk Limited | Combination therapies using HDAC inhibitors |
US7772238B2 (en) | 2005-04-20 | 2010-08-10 | Merck Sharp & Dohme Corp. | Benzothiophene hydroxamic acid derivatives |
US7834034B2 (en) | 2005-04-20 | 2010-11-16 | Merck Sharp & Dohme Corp. | Benzothiophene derivatives |
US7872024B2 (en) | 2005-04-20 | 2011-01-18 | Merck Sharp & Dohme Corp. | Benzothiophene hydroxamic acid derivatives with carbamate, urea, amide and sulfonamide substitutions |
US9957227B2 (en) | 2005-05-13 | 2018-05-01 | Topotarget Uk Limited | Pharmaceutical formulations of HDAC inhibitors |
US8835501B2 (en) | 2005-05-13 | 2014-09-16 | Topotarget Uk Limited | Pharmaceutical formulations of HDAC inhibitors |
US9856211B2 (en) | 2005-05-13 | 2018-01-02 | Topotarget Uk Limited | Pharmaceutical formulations of HDAC inhibitors |
US8138198B2 (en) | 2005-05-18 | 2012-03-20 | Angibaud Patrick Rene | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase |
WO2008041053A2 (en) | 2005-05-20 | 2008-04-10 | Methylgene, Inc. | Inhibitors of vegf receptor and hgf receptor signaling |
US8093264B2 (en) | 2005-05-20 | 2012-01-10 | Methylgene Inc. | Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling |
US8329726B2 (en) | 2005-05-20 | 2012-12-11 | Methylgene Inc. | Inhibitors of VEGF receptor and HGF receptor signaling |
US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
US7589197B2 (en) | 2005-06-14 | 2009-09-15 | Taigen Biotechnology | Pyrimidine compounds |
JP2007001885A (en) * | 2005-06-21 | 2007-01-11 | Univ Kansai | Carboxamide derivative |
JP4528918B2 (en) * | 2005-06-21 | 2010-08-25 | 学校法人 関西大学 | Carboxamide derivatives |
US8158825B2 (en) | 2005-06-24 | 2012-04-17 | Merck Sharp & Dohme Corp. | Modified malonate derivatives |
US7741494B2 (en) | 2005-07-14 | 2010-06-22 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US7732475B2 (en) | 2005-07-14 | 2010-06-08 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
WO2007055941A2 (en) | 2005-11-03 | 2007-05-18 | Merck & Co., Inc. | Histone deacetylase inhibitors with aryl-pyrazolyl motifs |
US9603926B2 (en) | 2005-11-10 | 2017-03-28 | Topotarget Uk Limited | Histone deacetylase (HDAC) inhibitors for the treatment of cancer |
US8828392B2 (en) | 2005-11-10 | 2014-09-09 | Topotarget Uk Limited | Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent |
US8686020B2 (en) | 2005-11-23 | 2014-04-01 | Merck Sharp & Dohme Corp. | Spirocyclic compounds |
US7834026B2 (en) | 2005-11-23 | 2010-11-16 | Merck Sharp & Dohme Corp. | Spirocyclic compounds |
US8349825B2 (en) | 2005-11-23 | 2013-01-08 | Merck Sharp & Dohme Corp. | Spirocyclic compounds |
US7544695B2 (en) | 2005-11-23 | 2009-06-09 | Merck & Co., Inc. | Spirocyclic compounds |
EP1973405A4 (en) * | 2006-01-12 | 2011-06-01 | Merck Sharp & Dohme | Hydroxyalkylarylamide derivatives |
EP1973405A2 (en) * | 2006-01-12 | 2008-10-01 | Merck & Co., Inc. | Hydroxyalkylarylamide derivatives |
US8114876B2 (en) | 2006-01-19 | 2012-02-14 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
US9078896B2 (en) | 2006-01-19 | 2015-07-14 | Janssen Pharmaceutica, N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
US8101616B2 (en) | 2006-01-19 | 2012-01-24 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
US8664223B2 (en) | 2006-01-19 | 2014-03-04 | Janssen Pharmaceutica N.V | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
US8163765B2 (en) | 2006-01-19 | 2012-04-24 | Janssen Pharmaceutica N.V. | Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase |
US8119650B2 (en) | 2006-01-19 | 2012-02-21 | Janssen Pharmaceutica N.V. | Aminophenyl derivatives as novel inhibitors of histone deacetylase |
US8168658B2 (en) | 2006-02-28 | 2012-05-01 | Merck Sharp & Dohme Corp. | Inhibitors of histone deacetylase |
US8598168B2 (en) | 2006-04-07 | 2013-12-03 | Methylgene Inc. | Inhibitors of histone deacetylase |
US8119685B2 (en) | 2006-04-26 | 2012-02-21 | Merck Sharp & Dohme Corp. | Disubstituted aniline compounds |
US8119652B2 (en) | 2006-05-18 | 2012-02-21 | Merck Sharp & Dohme Corp. | Aryl-fused spirocyclic compounds |
US7981874B2 (en) | 2006-07-20 | 2011-07-19 | Merck Sharp & Dohme Corp. | Phosphorus derivatives as histone deacetylase inhibitors |
EP2966078A2 (en) | 2006-10-28 | 2016-01-13 | MethylGene Inc. | Inhibitors of histone deacetylase |
WO2008055068A2 (en) | 2006-10-28 | 2008-05-08 | Methylgene Inc. | Inhibitors of histone deacetylase |
EP2343286A1 (en) | 2006-10-28 | 2011-07-13 | Methylgene, Inc. | Dibenzo[b,f][1,4]oxazepine derivatives as inhibitors of histone deacetylase |
EP2489657A2 (en) | 2006-10-28 | 2012-08-22 | MethylGene Inc. | Inhibitors of histone deacetylase |
WO2008089436A3 (en) * | 2007-01-18 | 2008-12-24 | Takeda San Diego Inc | Crystalline forms of histone deacetylase inhibitors |
WO2008089436A2 (en) * | 2007-01-18 | 2008-07-24 | Takeda San Diego, Inc. | Crystalline forms of histone deacetylase inhibitors |
US8030344B2 (en) | 2007-03-13 | 2011-10-04 | Methylgene Inc. | Inhibitors of histone deacetylase |
US8354445B2 (en) | 2007-03-13 | 2013-01-15 | Methylgene Inc. | Inhibitors of histone deacetylase |
WO2008123395A1 (en) | 2007-03-28 | 2008-10-16 | Santen Pharmaceutical Co., Ltd. | Ocular hypotensive agent comprising compound capable of inhibiting histone deacetylase as active ingredient |
US8461189B2 (en) | 2007-06-27 | 2013-06-11 | Merck Sharp & Dohme Corp. | Pyridyl derivatives as histone deacetylase inhibitors |
US8389553B2 (en) | 2007-06-27 | 2013-03-05 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
US9096559B2 (en) | 2007-06-27 | 2015-08-04 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
US8642809B2 (en) | 2007-09-25 | 2014-02-04 | Topotarget Uk Ltd. | Methods of synthesis of certain hydroxamic acid compounds |
US8372849B2 (en) | 2008-04-21 | 2013-02-12 | Taigen Biotechnology Co., Ltd. | Heterocyclic compounds |
US9796664B2 (en) | 2008-09-03 | 2017-10-24 | Biomarin Pharmaceutical Inc. | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors |
US9265734B2 (en) | 2008-09-03 | 2016-02-23 | Biomarin Pharmaceutical Inc. | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors |
EP2532657A2 (en) | 2008-10-14 | 2012-12-12 | Sunshine Lake Pharma Co., Ltd | Compounds and methods of use |
US9023834B2 (en) | 2008-11-13 | 2015-05-05 | Taigen Biotechnology Co., Ltd. | Lyophilization formulation |
WO2010110545A2 (en) | 2009-03-27 | 2010-09-30 | 주식회사종근당 | Novel hydroxamate derivative, a production method for the same, and a pharmaceutical composition comprising the same |
US8466161B2 (en) | 2009-03-27 | 2013-06-18 | Chong Kun Dang Pharmaceutical Corp. | Hydroxamate derivative, a production method for the same, and a pharmaceutical composition comprising the same |
US8217079B2 (en) | 2010-03-26 | 2012-07-10 | Italfarmaco Spa | Method for treating Philadelphia-negative myeloproliferative syndromes |
US9540395B2 (en) | 2011-02-28 | 2017-01-10 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
WO2012118632A1 (en) | 2011-02-28 | 2012-09-07 | Ning Xi | Substituted quinoline compounds and methods of use |
US10301323B2 (en) | 2011-02-28 | 2019-05-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
US10526346B2 (en) | 2011-02-28 | 2020-01-07 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
US10981933B2 (en) | 2011-02-28 | 2021-04-20 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
US9908899B2 (en) | 2011-02-28 | 2018-03-06 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
US9512143B2 (en) | 2011-02-28 | 2016-12-06 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
US10280182B2 (en) | 2011-02-28 | 2019-05-07 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
KR101528617B1 (en) * | 2011-10-28 | 2015-06-19 | 주식회사 종근당 | Hydroxamate Derivatives for HDAC Inhibitor, and the pharmaceutical composition comprising thereof |
WO2014022117A1 (en) | 2012-07-28 | 2014-02-06 | Calitor Sciences, Llc | Substituted pyrazolone compounds and methods of use |
WO2014022116A2 (en) | 2012-07-28 | 2014-02-06 | Calitor Sciences, Llc | Substituted pyrazolone compounds and methods of use |
EP3299019A1 (en) | 2012-11-14 | 2018-03-28 | Calitor Sciences, LLC | Heteroaromatic compounds as pi3 kinase modulators and methods of use |
WO2014130375A1 (en) | 2013-02-21 | 2014-08-28 | Calitor Sciences, Llc | Heteroaromatic compounds as pi3 kinase modulators |
US10029988B2 (en) | 2013-03-15 | 2018-07-24 | Biomarin Pharmaceutical Inc. | HDAC inhibitors |
US10428028B2 (en) | 2013-03-15 | 2019-10-01 | Biomarin Pharmaceutical Inc. | HDAC inhibitors |
US9878986B2 (en) | 2013-04-29 | 2018-01-30 | Chong Kun Dang Pharmaceutical Corp. | Compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same |
WO2014178606A1 (en) | 2013-04-29 | 2014-11-06 | Chong Kun Dang Pharmaceutical Corp. | Novel compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same |
EP3769757A3 (en) * | 2013-10-18 | 2021-10-06 | The General Hospital Corporation | Imaging histone deacetylases with a radiotracer using positron emission tomography |
KR20150068923A (en) | 2013-12-12 | 2015-06-22 | 주식회사 종근당 | Aza-indole Derivatives for HDAC Inhibitor, and the pharmaceutical composition comprising thereof |
US9650379B2 (en) | 2013-12-12 | 2017-05-16 | Chong Kun Dang Pharmaceutical Corp. | Azaindole derivatives as selective histone deacetylase (HDAC) inhibitors and pharmaceutical compositions comprising the same |
KR20150081132A (en) | 2014-01-03 | 2015-07-13 | 주식회사 종근당 | Indole Derivatives Compound, and the pharmaceutical composition comprising the same |
US9636298B2 (en) | 2014-01-17 | 2017-05-02 | Methylgene Inc. | Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs |
WO2016190630A1 (en) | 2015-05-22 | 2016-12-01 | Chong Kun Dang Pharmaceutical Corp. | Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same |
US11420950B2 (en) | 2015-05-22 | 2022-08-23 | Chong Kun Dang Pharmaceutical Corp. | Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same |
WO2017067447A1 (en) | 2015-10-19 | 2017-04-27 | Sunshine Lake Pharma Co., Ltd. | A salt of egfr inhibitor, crystalline form and uses thereof |
US10688047B2 (en) | 2015-11-03 | 2020-06-23 | Italfarmaco Spa | Physically and chemically stable oral suspensions of givinostat |
WO2018054960A1 (en) | 2016-09-21 | 2018-03-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting and treating resistance to chemotherapy in npm-alk(+) alcl |
US11938134B2 (en) | 2017-03-10 | 2024-03-26 | Eikonizo Therapeutics, Inc. | Metalloenzyme inhibitor compounds |
Also Published As
Publication number | Publication date |
---|---|
EP1590340A1 (en) | 2005-11-02 |
JP2006514998A (en) | 2006-05-18 |
JP3908773B2 (en) | 2007-04-25 |
CA2515338A1 (en) | 2004-08-19 |
HK1087707A1 (en) | 2006-10-20 |
AU2004210016B2 (en) | 2009-10-08 |
EP1590340B1 (en) | 2010-04-07 |
US20060058298A1 (en) | 2006-03-16 |
CN1723207A (en) | 2006-01-18 |
MXPA05008246A (en) | 2005-10-05 |
AU2004210016A1 (en) | 2004-08-19 |
DK1590340T3 (en) | 2010-07-19 |
KR100893804B1 (en) | 2009-04-20 |
DE602004026407D1 (en) | 2010-05-20 |
CA2515338C (en) | 2008-09-16 |
US6897220B2 (en) | 2005-05-24 |
ATE463490T1 (en) | 2010-04-15 |
KR20050098228A (en) | 2005-10-11 |
ES2341857T3 (en) | 2010-06-29 |
BRPI0407195A (en) | 2006-02-14 |
US20040142953A1 (en) | 2004-07-22 |
US7838520B2 (en) | 2010-11-23 |
CN100540547C (en) | 2009-09-16 |
PT1590340E (en) | 2010-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100893804B1 (en) | Inhibitors of histone deacetylase | |
US7595343B2 (en) | Inhibitors of histone deacetylase | |
US7868204B2 (en) | Inhibitors of histone deacetylase | |
AU2002327627A1 (en) | Inhibitors of histone deacetylase | |
CA2559733C (en) | Inhibitors of histone deacetylase | |
US8088805B2 (en) | Inhibitors of histone deacetylase | |
AU2006252047B2 (en) | Inhibitors of histone deacetylase | |
TWI415606B (en) | Inhibitors of histone deacetylase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005518241 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057009963 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004801769X Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004707852 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004210016 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/A/2005/008246 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2515338 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1604/KOLNP/2005 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2004210016 Country of ref document: AU Date of ref document: 20040204 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004210016 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057009963 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004707852 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0407195 Country of ref document: BR |